

Review

Unlocking Genetic Mysteries during the Epic Sperm Journey toward Fertilization: Further Expanding *Cre* Mouse Lines

Pengyuan Dai [†], Chaoye Ma [†], Chen Chen, Min Liang, Shijue Dong, Hao Chen  and Xiaoning Zhang ^{*}

Institute of Reproductive Medicine, Medical School, Nantong University, Nantong 226001, China; pengyuandai@ntu.edu.cn (P.D.); 2113310057@stmail.ntu.edu.cn (C.M.); 2113510009@stmail.ntu.edu.cn (C.C.); 2013510008@stmail.ntu.edu.cn (M.L.); 2113310047@stmail.ntu.edu.cn (S.D.); chen hao@ntu.edu.cn (H.C.)

* Correspondence: zhangxn@ntu.edu.cn

[†] These authors contributed equally to this work.

Abstract: The spatiotemporal expression patterns of genes are crucial for maintaining normal physiological functions in animals. Conditional gene knockout using the cyclization recombination enzyme (*Cre*)/locus of crossover of P1 (*Cre/LoxP*) strategy has been extensively employed for functional assays at specific tissue or developmental stages. This approach aids in uncovering the associations between phenotypes and gene regulation while minimizing interference among distinct tissues. Various *Cre*-engineered mouse models have been utilized in the male reproductive system, including *Dppa3-MERCre* for primordial germ cells, *Ddx4-Cre* and *Stra8-Cre* for spermatogonia, *Prm1-Cre* and *Acrv1-iCre* for haploid spermatids, *Cyp17a1-iCre* for the Leydig cell, *Sox9-Cre* for the Sertoli cell, and *Lcn5/8/9-Cre* for differentiated segments of the epididymis. Notably, the specificity and functioning stage of *Cre* recombinases vary, and the efficiency of recombination driven by *Cre* depends on endogenous promoters with different sequences as well as the constructed *Cre* vectors, even when controlled by an identical promoter. *Cre* mouse models generated via traditional recombination or CRISPR/Cas9 also exhibit distinct knockout properties. This review focuses on *Cre*-engineered mouse models applied to the male reproductive system, including *Cre*-targeting strategies, mouse model screening, and practical challenges encountered, particularly with novel mouse strains over the past decade. It aims to provide valuable references for studies conducted on the male reproductive system.

Keywords: *Cre* recombinase; *Cre/LoxP*; conditional knockout; germ cells; testes; epididymis



Citation: Dai, P.; Ma, C.; Chen, C.; Liang, M.; Dong, S.; Chen, H.; Zhang, X. Unlocking Genetic Mysteries during the Epic Sperm Journey toward Fertilization: Further Expanding *Cre* Mouse Lines. *Biomolecules* **2024**, *14*, 529. <https://doi.org/10.3390/biom14050529>

Academic Editor: Peter Boag

Received: 22 March 2024

Revised: 24 April 2024

Accepted: 26 April 2024

Published: 28 April 2024



Copyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Conditional knockout (cKO) with recombinant enzymes allows for the removal of targeted genes to investigate their functions in physiological processes. Recombinase systems, including the cyclization recombination enzyme/locus of crossover of P1 (*Cre/LoxP*), *vCre/vLoxP*, *sCre/sLoxP*, *Flp/FRT*, *Dre/Rox*, and *Vika/Vox* [1–5], are utilized with *Cre/LoxP* being the most prevalent. *Cre*, a 38-kDa recombinase with site specificity, has been an in vivo molecular tool for over 30 years [6,7]. It recognizes DNA sequences between two *LoxP* sites (Figure 1A). The target DNA sequences flanked by *LoxP*, engineered artificially, are termed “floxed” and can be specifically ablated by *Cre* driven by the promoters of cell-specific genes after recombining downstream of the promoters via transgenic technology or knock-in (KI) into endogenous genic loci [8,9]. However, in most cases, the promoter in *Cre*-constructed vectors is incomplete and lacks distal regulatory elements (e.g., enhancers), which further reduces transcription efficiency (Figure 1B). In addition, the randomness of genomic insertions can result in uncontrollable recombination sites [10] and may exert toxic effects when multiple copies are expressed in cells [9]. Notably, as the homozygous ectopic expression of *Cre* lines behaves more unpredictably, the heterozygous *Cre*-engineered mouse was generally crossed with the flox-transgenic mouse, significantly decreasing breeding efficiency. Furthermore, the KI approach facilitates gene insertion

into well-defined genic loci [11]. The CRISPR/Cas9 system, a DNA targeting and editing approach, has been broadly employed to establish *Cre* recombination mouse models driven in situ by target promoters after site-directed *Cre* insertion [12]. This method requires less time and is less costly for generating the desired transgenic mouse lines [13]. Functional gene investigation employing *Cre* transgenic mouse strains generated by CRISPR/Cas9 is more reliable and repeatable because the insertion locus is clear, promising endogenous gene expression away from interference to a large extent [13] (Figure 1B).




Figure 1. (A) DNA excising mediated by the *Cre-LoxP* system. The mouse DNA was flanked with *LoxP* sites. *Cre* catalytic activity was driven by the exogenous promoters and removed the target exon between *LoxP* sites after *Cre* recombinase translocated into the nucleus. (B) Two kinds of gene recombination modes. (1) Gene integration via a conventional transgenic approach was inserted into the host genome randomly with the unpredictable recombination site and multiple integrations (left panel); (2) Cas9 was directed to the target locus and cut double-stranded DNA after binding to sgRNA. The exogenous genes were knocked-in by homology-directed repair efficiently and inherited stably (right panel).

Spermatogenesis, which occurs in seminiferous tubules as the foundation of male fertility, is a complex process that produces mature gametes. It involves spermatogonia proliferation and differentiation into spermatocytes, spermatid generation through meiosis, and spermatozoa release into the tubule lumen after spermiogenesis [14]. Any aberration in these processes may impede fertilization. A systematic and in-depth investigation of the mechanisms regulating the orchestrated stages of spermatogenesis is crucial for treating male infertility or, conversely, the design of male contraceptives that target the desired developmental stages. *Cre/LoxP* recombination has been extensively utilized in specific DNA modifications targeting spermatogenic cells, such as *Ddx4-Cre* [15] for spermatogonia, *Sycp1-Cre* [16] for spermatocytes, and *Prm1-Cre* [17] for spermatids. Hammond et al. (2009) [18] and Smith et al. (2011) [19] reviewed genetic tools, including *Cre* recombinases specific for male and female germ cells and markers used to characterize cellular behavior or purify living germ cells. However, many subsequent reports with conditional ablations using these *Cre* have shown that they are not as specific or efficient as previously thought. Issues such as the efficiency and specificity of *Cre* recombinase not aligning with presuppositions need to be addressed given the widespread availability of abundant *Cre*-engineered lines, including heterotopic expression of non-target tissues [20,21], leakage [22], the instability of KO efficiency [17,23], and global KO [15,24]. Furthermore, various novel *Cre* mouse lines have been engineered with the request for more detailed dissection in critical cellular processes during spermatogenesis over the past decade (Figure 2). In this review, we summarize the novel advances in these events, especially the removal of targets in the primordial germ cells (PGCs), testis, epididymis, prostate, and seminiferous duct, as well as the unintended consequences of crossing with *Cre* mouse lines to provide a referential basis for studies investigating the functional roles of genes in male reproduction.




Figure 2. Schematic diagram showing the established novel mouse strains and *Cre* lines used widely in the male reproductive system. (A) *Cre* models in the testes specific for each primary cell type, including PTM and peritubular myoid cells. SC, Sertoli cell; LC, Leydig cell; PGCs, primordial germ cells; Spg, spermatogonia; Spc, spermatocyte; Spd, spermatid; VE, vascular endothelial cells; MC, myeloid lineage cell (B) The *Cre* lines specific for IS, caput, corpus, cauda, and vas deferens.

2. *Cre* Lines for PGCs and Spermatogonia

2.1. *Ddx4-Cre*

Ddx4, also known as *Vasa* or *Mvh*, is located on mouse chromosome 13 and is an ATP-dependent RNA helicase that is highly conserved in mammals, belonging to the DEAD (Asp-Glu-Ala-Asp) box family [25]. *Ddx4* is primarily detected in germ cells with lower levels in other tissues such as the thymus and pancreas [26], appearing as early as embryonic day 10.5–12.5 (E10.5–12.5) and persisting in both the testes and ovaries throughout life [27,28]. Male infertility ensues after *Ddx4* KO [27], while the *Ddx4* mutation has minimal influence on female fertility, although oocytes with elevated levels of *Ddx4* have been observed [29]. *Ddx4-Cre* lines (Strain #:006954) are available for functional analysis, particularly concerning genes implicated in spermatogonial establishment, maintenance, and differentiation. Notably, *Ddx4-Cre*-mediated target recombination efficiently initiates at E15, as indicated by the *Rosa26-lacZ* reporter, but it was inconsistent with its endogenous expression [30]. Recently, an improved *Cre* (*iCre*) line targeted by CRISPR/Cas9 exhibited higher efficiency in PGCs, with *Cre* activity initiated as early as E10.5. Furthermore, the probability of descendants with global KO from paternal *Cre* carriers was lower than that of *Ddx4-Cre* lines [30] for special floxed alleles, such as *Cripto^{fllox}* [15]. However, both types of *Cre* carriers in females can lead to offspring with global KO, demonstrating a robust maternal effect [15,30]. Moreover, reports on the minimal ectopic activity of *Ddx4-Cre/iCre* recombinase have surfaced [15,30].

CreER constructs have been used for temporal gene ablation, with *Cre* fused to the mutated human estrogen receptor (ER) and named *CreER* [31]. *CreER^T*, as a human ER variant, was more sensitive to 4-hydroxytamoxifen (4-OHT), the metabolite of tamoxifen (TAM), compared to endogenous 17 β -estradiol [32,33]. The mutants of *CreER^{T1}* and *CreER^{T2}* display even higher sensitivity to 4-OHT [34]. Moreover, *CreER^{T2}* has been used extensively due to its robust activation at a specific stage upon TAM treatment with minimal background in *Cre* activity [34]. Given the unknown insertion site of *Ddx4-CreER^{T2}* acquired through random gene recombination, Hoai et al. established a novel bicistronic mouse strain via CRISPR/Cas9, known as B6-*Ddx4^{em1(CreER^{T2})Utr}* [20]. However, infertility was found in the homozygous mouse line, manifesting as spermiogenesis arrest and absent mature spermatozoa. The ATPase activity of *Ddx4* was halved in homozygotes, possibly due to the additional 25 amino acid residues introduced by the *P2A* sequence, which protects

Ddx4 from being knocked out. Additionally, *Cre* recombination is primarily activated in the testes and ovaries but not in the pancreas or thymus [20]. In summary, novel-inducible B6-*Ddx4^{em1(CreERT2)Utr}* mice are available for studying sterility at specific spermatogenic stages, and the use of the heterozygote *Cre* line during mating is recommended.

2.2. *Stra8-Cre*

Stimulated by retinoic acid 8 (*Stra8*), localized on mouse chromosome 6, it is specifically expressed in germ cells and is essential for initiating meiosis during spermatogenesis and oogenesis, the deficiency of which leads to abnormal chromosomal behavior [35]. In females, *Stra8* expression coincides with oocyte meiosis initiation at E13, with the peak at E14.5, and declines sharply after E16.5 [36]. In males, *Stra8* expression is detected at 5 days post-parturition (DPP), with reports also indicating expression at 3 DPP, persisting in preleptotene spermatocytes [37]. As early as 2008, the *Stra8-Cre* line (Strain #:008208) was generated to study male germ cell development with a recombination efficiency of >95%, whereas the *Cre* line did not work in transgenic female mice [38]. The diverse strategies of mating with *Stra8-Cre* resulted in different efficiencies and offspring phenotypes. Bao et al. constructed an *iCre* regulated by the *Stra8* promoter, excising the *Mov10l1* flox allele with high efficiency in spermatogenic cells. However, it failed to remove two *Mov10l1* flox alleles in single breeding, and the testicular phenotypes were less severe compared to completely knocked-out mice [39]. Additionally, Balnco et al. observed the presence of the DOLT1 protein in offspring born to mice with a single allele of *Dot1l* excised by the *Stra8-Cre* recombinase line [40]. This discrepancy could stem from the transgenic mice driving *Cre* expression using only part of the *Stra8* promoter, which differs from the endogenous *Stra8* expression profile. The uncertain insertion site and varying copies of *Cre* may also result in lower KO efficiency. Recently, the functional responsive elements in the 2.9 kb promoter lying upstream of 1.4 kb promoters that promised optimal *Stra8* expression in vivo were characterized [41]. Therefore, *Cre* inserted into the targeted locus of *Stra8* may exhibit optimal recombinase activity. The CRISPR/Cas9-mediated targeted mutation was employed to insert *Cre* or *EGFP-Cre* at the stop codon of *Stra8* to study specific genes involved in spermatogenesis [42]. Avery et al. knocked in engineered *P2A-Cre* via the CRISPR/Cas9 system and recombinase activity without disturbing *Stra8* expression or mouse fertility. It is worth noting that the *Stra8-P2ACre* line also exhibited *Cre* activity in female mouse germ cells at E12.5–E16.5 [43]. Xue et al. generated germline-specific *Nat10* cKO females using *Stra8-GFPCre* or *Zp3-Cre* KI and revealed *Nat10*-indispensable oocyte meiosis progression, growth, and maturation [44]. The *Stra8-Cre* female strain constructed by targeted insertion contributes to studies focusing on oogenesis; however, offspring suffering from global KO appeared upon mating with the female *Stra8-Cre* line because of the long half-life of *Stra8-Cre* expressed in the oocyte.

2.3. *PrP-CreER^T*

Prp is primarily localized in the central nervous system (CNS) and shows low expression in the spleen, kidney, heart, and testes [45]. Specific *PrP* fragments or reporter genes were engineered for expression in the CNS. Philipp et al. reported that one of the transgenic lines expressing *CreER^T* induced by TAM and driven by 7.5 kb *PrP* fragments was restricted to the testis, with recombination occurring in particular in the spermatogonia, spermatocytes, and spermatids [46]. Following treatment with TAM for 6 days, approximately 30% of the floxed alleles underwent recombination in the testis without ectopic expression in other tissues, and even after 6 weeks of induction, 50% of seminiferous tubules still showed *Cre* activity [46]. Despite lower recombinant activity, this mouse strain provides a relatively specific tool for the genetic analysis of germ cells.

2.4. *Dppa3-MERCre*

Dppa3 (also named *Stella* or *Pgc7*) marks primordial germ cells emerging at E7.25, with robust expression persisting at around E15.5 in males and E13.5 in females [47,48].

Dppa3 is also expressed from the zygotic stage onward and remains in all blastocyst cells at E4.5 [48,49]. A novel transgenic mouse line (*Dppa3-MERCre*) was generated by Takayuki et al., and *Cre* recombinase expression was regulated by the *Dppa3* promoter under simultaneous induction with 4-OHT, binding to domains flanking the *Cre* sequence [50]. Additionally, these strains demonstrated specific and efficient KO outcomes in PGC development, preimplantation embryos, and oocyte growth after 4-OHT stimulation [50]. Thus, *Dppa3-MERCre* can serve as a strain for exploring gene function during germ cell lineage development. Inducible KO also contributes to defining the function of specific genes causing embryonic lethality after target silencing. However, determining the optimal dose of the inductive agent before treatment in pregnant models is crucial to avoid miscarriage or other toxic effects associated with the drug.

2.5. *Eomes-CreER^T*

Eomesodermin (EOMES) is a T-box transcription factor crucial for intrinsic functions in immune cell development [51]. In addition, *Eomes* is vital for gastrulation formation and trophoblast development. Mutation in *Eomes* blocks at the blastocyst phase, preventing differentiation into trophoblasts after *Eomes* inactivation in the trophectoderm, suggesting its potential role in trophoblast stem cell physiology [52]. Stefanie et al. established an inducible *CreER^T* that carried 4-OHT in the MEFs sequence at the *Eomes* locus (*Eomes-CreER^T*) to study *Eomes* expression in pluripotency reprogramming in adult somatic mammalian cells [53]. Moreover, *Eomes* is localized in a subset of undifferentiated spermatogonia and contributes to regeneration after chemical injury and spermatogenesis regulation [54]. This suggests its potential to uncover target functions by establishing *CreER^T* recombination in germ cell lines via in situ TAM induction.

2.6. *Ngn3-Cre*

NGN3 is a marker of postnatal undifferentiated spermatogonial cells from 3 DPP [55] and is localized in the developing CNS, adult enteroendocrine cells, and pancreas [56]. Two *Ngn3-Cre* mouse strains were established for functional research on SSCs and spermatogenesis. Originally, *Cre* recombinase was constructed on an artificial bacterial chromosome (BAC) and inserted into the mouse *Ngn3* locus 23 kb region [57]. A strong recombination signal was observed in the seminiferous tubules at 7 DPP, corresponding to the start of endogenous *Ngn3* expression [57], with an efficiency close to 100% observed in juvenile and adult testes [57–59]. Another *Ngn3-Cre* mouse line (Strain #:005667) was generated by inserting a *Cre* recombinase cassette next to the start codon of the endogenous *Ngn3* [60], with *Cre* catalytic activity appearing at 7 DPP [61,62] (Figure 2). Studies focusing on the action of SSCs [63,64] and germline development [65] during spermatogenesis have been conducted using this transgenic strain. Given the multiple localizations of NGN3 in the pancreas, CNS, and enteroendocrine cells, spatial specificity is gaining increasing attention.

2.7. Other *Cre* Lines for PGCs and Spermatogonia

Other *Cre* lines available for functional studies of PGCs and spermatogonial targets are described in Table 1. *Tnap-Cre* in PGCs was specifically designed to excise targets at E9.5–E10.5, while broad expression patterns were detected in the neural tube, placenta, labyrinthine region, and intestine after mid-gestation, achieving an efficiency of approximately 50% [66]. *Nanos3* localizes to migrating PGCs and stages after settling in the gonads of both males and females. *Nanos3-Cre* bioactivity was observed at E7.75, with an efficiency ranging from 11 to 25% [67]. *Blimp1*-positive cells considered the progenitors of PGCs in both sexes, were expressed persistently from E6.25 to E13.5 [68,69]. *Blimp1-Cre* was found to be activated at E7.8 in PGCs, with a positive ratio of 55–78% [68]. However, as *Blimp1* is also expressed in the retina, limbs, heart, pharynx, and B and T lymphocytes [70], *Blimp1-Cre* may not be suitable for all functional experiments. Tamoxifen-inducible ubiquitin C (*UBC-CreER^{T2}*) [71,72] and *ROSA26-CreER^{T2}* [73] were utilized for special target ablation in adult spermatogonia post-tamoxifen administration, showing high efficiency without

detectable *Cre* recombination activity in somatic cells of the testis and other germ cells. Nonetheless, *UBC-CreER^{T2}* activity was found in the somatic cells of 4-week mice testes, indicating an age-dependent *Cre* recombinase property [74,75]. Considering the broad expression of *UBC* and *ROSA26*, the predicted SSC phenotypes may be affected by functional defects in other tissues. *Cre* fused with the mouse mutant *ER* ligand-binding region is known as *MerCreMer* [76]. *Oct-4* in PGCs starts at E7.5 in developmental embryos [77]. The *Oct4-MerCreMer* mouse line was used to perform the genetic analyses of undifferentiated spermatogonia, including As, Apr, and Aal types [78,79]. However, because *Oct4* is expressed in various tissues during postnatal development, such as the skin, liver, and pancreas [80], the cKO phenotype should be evaluated to exclude other disturbances.

3. *Cre* Recombination Lines for Spermatocytes

3.1. *Sycp1-Cre*

Synaptonemal complex protein 1 (SYCP1), primarily constituting the synaptonemal complex in meiosis, mainly functioned in recombination and XY body formation during leptotene to early pachytene stages [81]. Vidal et al. generated *Sycp1-Cre* mouse lines (Strain #:003466) and verified the recombination efficiency in mice harboring *Sycp1-Cre* and another transgene flanked by *LoxP*. They found that descendants of male double-transgenic mice mating with normal females were widely excised from the *LoxP*-flanked sequence. Even males were hemizygous for *Sycp1-Cre*, with the targets being removed in offspring without the *Cre* gene, indicating that recombination occurred during paternal spermatogenesis [16]. Additionally, the *Sycp1-Cre* driving target KO was restricted in the testis exclusively, and the flox-flanked segments were never altered in female progeny [16], likely due to the heterotopic transgenic expression initiated by partial promoters of *Sycp1*. Sanny et al. also confirmed that the specificity of *Sycp1-Cre* was restricted in the testes by crossing with R26R reporter transgenic mice, with recombination occurring in zygotene spermatocytes. Higher KO efficiency was observed in the entire meiosis stage, indicating that the *Sycp1-Cre* line is suitable for gene analysis during the germinal differentiation process [82].

Sycp1-Cre recombination activity decreased in the second generation during meiosis. This defect was associated with cytosine methylation, occurring in *LoxP* and transgenic sequences and extending to longer sequences in chromosomes. The allelic locus was also affected by a structure similar to the transvection defined in *Drosophila* [22]. In addition, Reza et al. created germ cell lines that were conditional knocked-out *Ikkβ* through mating with *Sycp1-Cre* mice; however, approximately 43% of the *LoxP*-flanked sequence was recombinant in offspring due to the epigenetic modification of *LoxP* in fourth- and fifth-generation (F4 and F5) mice [83]. The sodium bisulfite treatment sequencing revealed that methylated *LoxP* site cytosines were only found in F4 or F5 mice rather than in re-derived F1 *Ikkβ^{fl/fl}* mice unmated with *Sycp1-Cre*. The methylated *LoxP* sites were derived from *Sycp1-Cre*-sired *IKKβ-LoxP* alleles in paternal lines, while maternal *LoxP* was unmethylated [83]. Despite its suitability for gene analysis during germinal differentiation, *Sycp1* presents epigenetic modifications and low recombination efficiency that cannot be neglected.

3.2. *Prl3b1-Cre*

Prolactin family 3, subfamily B, member 1 (*Prl3b1*) is localized in mouse chromosome 13, and its expression has been detected in the nervous system, eye, and epithelium of the digestive tract in mid-to-late developing embryos [84]. *Prl3b1* is found in testicular germline cells, particularly in spermatocytes and haploid spermatids [85]. The *Cre* recombinase mouse line under the control of a 2.5 kb *Prl3b1* promoter (*Prl3b1-Cre*) was generated, and efficiency and specificity analyses were conducted by mating with R26GRR mice expressing the fluorescent protein, tDsRed, after *Cre* activation [85]. *Cre* recombination activity was determined to be limited to the testis, epididymis, and seminiferous ducts. A strong fluorescence signal was observed from elongated spermatids and spermatozoa in seminiferous tubules, with 74% recombination efficiency detected in germ cells after in vitro fertilization [85]. In summary, the *Prl3b1-Cre* strain offers a powerful tool for investigating

the genes involved in the spermatogenic process, owing to its robust specificity in germ cells, which is superior to that of the *cKit-Cre*, *Pgk2-Cre*, *Hspa2-Cre*, and *Syn-Cre* mouse strains reviewed in detail by Lee Smith [19] (Table 1).

3.3. *Wisp3-Cre*

Wisp3, activated by the Wnt-1 signaling pathway, is involved in multiple cellular physiological functions and carcinogenesis, including colon and breast cancers. Its mutation is related to progressive pseudorheumatoid arthritis, which is a type of autosomal recessive hereditary disease [86]. However, the mutation or overexpression of *Wisp3* in mice results in no visible phenotypes compared to wild-type animals [87]. To further investigate the physiological actions and spatial expression of *Wisp3* in mice, the *Wisp3-GFPCre* KI mouse line was established, with *GFPCre* inserted into the first exon of *Wisp3*, replacing *Wisp3* expression with GFP and *Cre*. *Cre* recombination activity has been reported by mating with females carrying the *ROSA26^{mTmG}* allele. Higher levels of *Cre*-mediated recombination were observed only in the testes, especially during the prophase of meiosis I in spermatocytes. The recombinant offspring accounted for 7% of those born to females with two double heterozygotes with no recombination activity in the ovary [88]. In addition, William et al. concluded that Aurora A Kinase (AURKA) plays a role in spermatid physiology and mouse fecundity using the *Aurka* spermatocyte KO mouse strain, generated by crossing *Aurka^{fl/fl}* female mice with one floxed allele with *Wisp3-Cre* transgene male mice [89]. In conclusion, although *Wisp3* is not essential for mouse fertility, the male mice carrying the *Wisp3-Cre* allele contribute to exploring the role of genes in the meiosis I stage of spermatogenesis.

3.4. *Spo11-Cre*

DNA double-strand breaks (DSBs) are crucial for initiating meiotic recombination and are initiated by SPO11. *Spo11* mutation causes a synaptic defect in pachytene and leads to meiotic arrests in both males and females, resulting in the apoptosis of spermatocytes and oocytes [90]. Manuela et al. determined the physiological function of *JAM-C* in the germ cells of a cKO model in transgenic mice expressing *IRES-Cre* driven by *Spo11* during early meiosis [91]. Lyndaker et al. also generated *Spo11-IRES-Cre* mouse tools (Strain #:032646) to investigate the role of HUS1 in DSB repair during meiotic prophase I (Figure 2) [92]. However, the transgenic *Spo11* locus not only includes the entire *Spo11* promoter sequence but also fuses with the *IRES* sequence upstream of the start site [91,92]. Further studies found that the expression of *Spo11* in transgenic mice was disrupted by negative feedback, leading to a significant reduction in the *Spo11* level and a direct and substantial impact on the meiotic process [93]. The Jordan group found that the main defect in spermatogenesis occurs in spermatocytes rather than in spermatids after *Aurka* mutation in *Spo11-IRES-Cre* cKO models [92,94]. They did not note that endogenous *Spo11* function is disturbed by *Cre* recombination, which differs from the results obtained by William et al., who concluded that *Aurka* is required not only for spermatocyte maintenance but also for spermatid morphogenesis using *Aurka* spermatocyte KO mice excised by *Wisp3-Cre* [89]. In summary, the use of *Spo11-Cre* in the study of gene functions in spermatocytes is limited and has rarely been reported.

4. *Cre* Recombination Strains for Spermatids

4.1. *Tspy-Cre*

Human *Tspy*, localized on the Y chromosome, encodes proteins expressed in the testis and is conserved in placental mammals, including artiodactyl [95], rodents [96], and perissodactyl [97]. *Tspy* functions in the cell cycle with differentiation, indicating its role in spermatogonial development [98]. As *Tspy* was silenced naturally in experimental mice, human *Tspy*, including a 2.8 kb coding region with a 2.95 kb promoter region, was used to establish a transgenic mouse line to analyze *Tspy* physiological characteristics in the testis [99]. Mice harboring human *Tspy* (*hTspy*) presented normal phenotypes, and the counts of pachytene spermatocytes and spermatids did not change sharply compared to

wild-type controls [99]. Furthermore, the *hTspy-Cre* recombinant mouse was constructed in the control of a 2.4 kb *hTspy* promoter, and it was found that the *hTspy* recombination activity was mainly in round and elongated spermatids, as shown by EGFP immunostaining in the progenies born from double *hTspy-Cre/Z/EG* mice expressing EGFP, especially in the testis [100]. Additionally, EGFP is expressed in the ovary and in the central and peripheral nervous systems as early as E12.5. Thus, the *hTspy-Cre* transgenic mouse line can be used as a model for exploring gametogenesis. However, *Cre* activation in multiple tissues may result in an inaccurate determination.

4.2. *Prm1-Cre*

Endogenous protamine is expressed in the haploid stages of spermatogenesis [101], and exogenous genes fused with the *Prm1* proximal promoter are primarily limited to haploid spermatids [102,103] despite lower ectopic expression in the heart and temporal bone [104]. One type of *Prm1-Cre* mouse line (Strain #:003328) comprises a fusion of *Cre* with the 652 bp fragment of the mouse *Prm1* promoter. Recombination efficiency was primarily observed in male germ cells with non-significant functionality both in embryonic stem cell lines and somatic tissues from embryos or adult mice [17]. However, the recombination efficiency of *Prm1-Cre* is doubtful, with only about 50% reported when floxed *Pofut1* and *Mgat1* were silenced, as noted by Frank et al. [23]. Another *Prm1-Cre* mouse line developed by Schmidt et al. demonstrated the catalytic activity of *Prm1-Cre* recombinase in post-meiotic spermatids. However, all paternal *Cre*-bearing mice and *Cre*-modified male offspring modified by *Cre* from female founders were infertile. Further analysis revealed that 100% of abortive pregnancies were caused by spermatid chromosome rearrangements catalyzed by *Cre* recombinase in embryos acquired from wild-type females crossed with males carrying the *Cre* gene [105].

4.3. *Acrv1-iCre*

Cre recombinase specific to spermatids was established to be limited to haploid cells after meiotic division. Offsprings from mating floxed transgenic and heterozygote *Cre* recombination strains are the result of an inevitable part of haploid sperm being recombination-deficient without exhibiting presumptive phenotypes. Theoretically, approximately half of non-recombining sperm hold some promise for normal reproduction. Thus, increasing recombination efficiency is essential for targeting genes of interest in spermatids. Recently, an *Acrv1-iCre* mouse line was genetically engineered using CRISPR/Cas9 to selectively excise genetic segments in spermatids [106]. The expression of *iCre*, initiated by the promoters of *Acrv1*, which is specifically localized in stage 5–8 spermatids, efficiently deleted the floxed allele by more than 97%, as quantified by assessing the percentage of progeny with intact floxed alleles or deletion upon the mating type of *Rosa26^{Acrv1-iCre/+}* with *Dot11^{fl/fl}* [106]. The generation and characterization of the *Acrv1-iCre* recombination line by Julie et al. [106] contradicted the hypothesis that a small number of alleles in haploid spermatids would not be knocked out because of the common crossing approach. We assumed that *Cre* transcripts already functioned either prior to or during the second meiotic division process. *Cre*-negative spermatids can activate recombination activity through intercellular communication, such as exocytosis [107], which coincides with the concept that *Cre* can pass between haploid spermatozoa via cytoplasmic bridges [19]. Moreover, *Cre* transgenic mouse lines offer an advantageous technique for establishing global KO models to investigate large quantities of gene sequences in somatic tissues if normal reproductive behavior is observed after the genes in either early germ cells or haploid spermatozoa are excised.

4.4. *Elf5-Cre*

ELF5, an ETS transcription factor, is localized in the trophoblast lineages of the embryo as well as in the prostate, kidney, lungs, testes, and mammary gland during postnatal development [108–110]. Shuangbo et al. established an *Elf5-Cre* transgenic mouse line by co-injecting the constructed *2A-Cre* coding sequence with Cas9/sgRNA into the pronuclei,

and the *Cre* sequence was integrated into the exon of *Elf5* close to the stop codon to investigate the contribution of genes in placental development (Figure 2) [108]. Typically, *Cre* is activated in all trophoblast-derived lineages. Furthermore, a robust signal was detected in spermatids and sperm, suggesting a novel transgenic mouse strain for functional gene studies confined to the late stage of spermatogenesis [108]. However, due to the catalytic activity of *Elf5-Cre*, attention should be paid to its specificity and efficiency when studying genes of interest in haploid sperm.

Table 1. Characteristics of *Cre* models generated for male germline research.

Marker Strains	Germline Specific	Expression Outside of the Reproductive System	Initial Expression Phase	Transgenic (Tg)/Knock-In (KI)
<i>Oct4-MerCreMer</i> [78,79] (Strain #016829)	PGCs and undifferentiated spermatogonia	Pancreas, skin, intestine, kidney, etc. [80]	E7.5–8 [77]	KI
<i>Tnap-Cre</i> [66]	PGCs (around 50%)	Placenta, intestine and neural tube, labyrinthine region	E9.5–10.5	KI
<i>Nanos3-Cre</i> [67]	PGCs (11–25%)	NR	E7.75	KI
<i>Nanos2-MerCreMer</i> [111,112]	undifferentiated spermatogonia	NR	E13.5 [113]	Tg
<i>Blimp1-Cre</i> [68,114] Strain #008827	PGCs (55–78%)	B and T lymphocytes, retina, limbs, pharynx, and heart [70]	E6.25	Tg
<i>Tex101-iCre</i> [115,116] Strain #019893	Pro-spermatogonia and subsequent germ cells	NR	1 DPP	Tg
<i>Gfra1-CreER^{T2}</i> [117]	Undifferentiated spermatogonia	Kidney [118]	E9.5	KI
<i>UBC-CreER^{T2}</i> [71,72,74,75,119] Strain #:007001	Spermatogonia, testis, and somatic cells	Thymus, spleen, heart, muscle, brain, kidney, bone marrow [119]	NR	Tg
<i>Rosa26-CreER^{T2}</i> [73]	Spermatogonia	Other tissues in embryo and adult [120]	NR	KI
<i>Aqp2-Cre</i> [121] Strain #:006881	Spermatids	Kidney	NR	Tg
<i>Hspa2-Cre</i> [122,123] Strain #:008870	Spermatocyte and spermatids	Brain and embryo	Leptotene	Tg
<i>Pgk2-Cre</i> [124,125]	Spermatocyte and spermatids	Tissues in embryo [125]	NR	Tg
<i>Wnt7a-Cre</i> [126,127] Strain #036637-JAX	Spermatocyte	Uterine epithelium [127]	Mid-pachynema (12 DPP)	Tg
<i>cKit-Cre</i> [128]	Spermatocytes and spermatids	Mosaicism (20–100%)	NR	Tg
<i>CaMKIIα-Cre</i> [129,130] Strain #:005359	Testis germ cells	Brain	NR	Tg
<i>Syn1-Cre</i> [131,132] Strain #:003966	Spermatocytes	Neurons [132]	E12.5	Tg

NR: not reported.

5. *Cre* Transgenic Mice for Sertoli and Leydig Cells

Cre lines specific for Sertoli cells, including *Abp-Cre*, *Amh-Cre* (Strain #:007915), *Dhh-Cre* (Strain #:012929), and *Dmrt1-Cre*, have been used extensively and were described by Smith [19]. Here, novel *Cre* lines specific to Sertoli cells and their practical applications are described. *Sry* was exclusively detected in the supporting cells of genital ridges during E10.5–E12.5 and mediated the fate of supporting cells towards Sertoli cells [133]. *Sry-Cre* compromising the 9.9 kb *Sry* sequence under the controls of 5' and 3', untranslated regions of endogenous *Sry*, was constructed to explore the fate of *Sry*-positive cells [134] as well as the functional region of sex determination-related genes [135,136]. *Sox9* is expressed in multiple tissues and cells, including the CNS, intestine, and Sertoli cells, and regulates cell growth and differentiation during mouse embryogenesis. The *Sox9-Cre* transgenic line was generated by fusing *Cre* recombinase with an internal ribosome entry sequence and knocking it into the *Sox9* locus at the 3' untranslated region [137]. The systematic analysis of *Sox9-Cre/R26R* mice revealed that *Sox9*-positive cells, as progenitors, were conducive to a variety of cell types, including chondrocytes, Leydig cells in the testis, intestinal epithelial cells, and all cells in the pancreas and spinal cord of the mouse embryo

from E8 to E17 [137]. Therefore, the *Sox9-Cre* mouse line can be used for sex differentiation investigations because of its catalytic activity in early embryos. Yayoi et al. established a *Sox9-Cre/Nr5a1^{fl/fl}* mouse strain and concluded that *Nr5a1* plays a crucial role in mouse gonadal sex determination [138]. *Sox9-CreER* mice (Strain #:035092) were generated after *IRES-CreER^{T2}-SV40pA* cassettes integrating into endogenous *Sox9* at 3'UTR by the Cas9/RNA targeting method and have been applied in embryonic lineage tracing experiments after mating with *Rosa-stop-mTmG* mice [139]. However, *Sox9-Cre* was restricted in its application to males due to its recombinant activity in a broad range of tissues.

Cyp17-iCre (Strain #:028547) and *Cyp11a1-iCre* in Leydig cells were reviewed in 2011 with ectopic expression in the brain and adrenal glands [19]. Additionally, a second *Cyp11a1-iCre* transgenic line was generated by BAC construction comprising a 2.8 kb *Cyp11a1* and *iCre* sequence, and the *iCre* catalytic activity was controlled by the mouse promoter [140]. Laura et al. established another novel mouse line, *Cyp11a1-GC*, with dual characteristics: it not only silenced the endogenous *Cyp11a1* function but also simultaneously knocked-in *Cre* recombinase, which excises the genes of interest in steroidogenic cells without changes in the circulating testosterone concentration [141]. Annalucia et al. characterized the ability of viral vectors, including adenovirus, lentivirus, and adeno-associated virus (AAV), to deliver exogenous genes targeting Leydig cells in adult mouse testes and determined that AAV serotype 9 (AAV9) + neuraminidase transported the transgenes efficiently [142]. Moreover, AAV9-driven *Cre* was generated by the Diane group to delete endogenous glucocorticoid receptors in adult Leydig cells; the silencing efficiency of AAV9-*Cre* to AR was 48% 7 days after injection, which was higher than that of the *Cyp17a1-iCre* transgenic approach (28%) [143]. The AAV9 virus was found to infect germ cells of the testes from 3-week mice [144], possibly because these testes are not fully developed in immature mice, and the blood–testis barrier is not fully established. Thus, the AAV9-*Cre* silencing method is more suitable for exploring the genetics underlying the functions of adult Leydig cells, whereas the *Cyp17a1-iCre* model is more suitable for functional studies of developing Leydig cells.

The type II *Amh* receptor, *Amhr2*, is localized in the mesenchyme of the Müllerian duct, Leydig cells, Sertoli cells, and granulosa cells and initiates the degeneration of Müllerian ducts after binding with the anti-Müllerian hormone [145]. The *Amhr2-Cre* line (B6;129S7-*Amhr2^{tm3(cre)Bhr}*/Mmnc from the Mutant Mouse Regional Resource Centers) was generated by knocking in the targeting vector to the endogenous *Amhr2* loci (Figure 2) [146]. The catalytic activity of *Amhr2-Cre* was observed in both the Leydig and Sertoli cells of the testis, theca cells, and granulosa cells in the ovary [147,148]. The *Amhr2-Cre* mouse model has also been used as a genic toolkit for the study of testicular granulosa cell tumors [149]. Notably, *Amhr2-Cre* mice mating with (translocator protein) *Tspo*-floxed mice generated global *Tspo* KO mice instead of the *Tspo* cKO line [24], probably because of the genetic linkage of *Amhr2* with *Tspo*, which are expressed together during the early embryo stage. Thus, emphasis should be placed on whether global KO occurs when using the *Amhr2-Cre* mutation approach. Furthermore, the Chauvin group, collaborating with the Jackson Laboratory, developed *Amhr2-CreER^{T2}* mice (Strain #:037056) by the CRISPR/Cas9-mediated approach, which has been explored in determining the fate of cancer-associated mesothelial cells in ovarian cancer upon *Amhr2* induction by crossing with the *ROSA26^{mTmG}* mouse line [150]. The recombination efficiency of this novel mouse line requires further evaluation.

6. Cre Transgenic Models for Other Cells in the Testes

In addition to spermatogenic, Leydig, and Sertoli cells, various other cell types have been well established in the testes, including T cells, endothelial cells, peritubular myoid cells, mesenchymal (stromal) cells, macrophages, tenocytes, two pericyte subpopulations (with either smooth muscle or ECM-secreting properties), and a Leydig cell precursor population [151–153]. However, the functional characteristics of these cells contributing to spermatogenesis are yet to be elucidated, and their protein expression patterns have not

been identified. Several generalized *Cre* lines were used to investigate the gene function in these cells. *smMHC-Cre* (also called *Myh11-Cre*) (Strain #007742) for vascular smooth muscle cells and peritubular myoid cells (PTM) and *SM22-Cre* lines (Strain #:004746) for PTM were described by Smith [19]. *Myh11-Cre* was used to uncover the multiple functions of genes in testicular PTM. The synthesis of the testosterone-dependent glial cell line-derived neurotrophic factor (*GDNF*) in PTM cells was found to maintain the microenvironment of the spermatogonial stem cell (SSC) niche, together with Sertoli cells [154]. The initial recombination activity of the *Myh11-Cre* mouse line was detected at E12.5, and *Cre* efficiency was observed in all smooth muscles of adult mice, including the heart, bladder, lung, and testes [155]. The essential roles of *GDNF* [156] and *Gops5* [157] in PTM cells on mice reproductive function and postnatal development in PTM cells have been demonstrated in *Myh11-Cre* cKO models. Furthermore, tamoxifen-inducible *Myh11-CreER^{T2}* or *Myh11-DreER^{T2}* mouse strains virtually eliminated specific targets in PTM cells [158]. However, *Myh11-Cre* expression in the testes was not restricted to PTM cells and was also found in blood vessels; thus, interference may occur in the prospective phenotype in cKO mice [159]. Moreover, *Cx3c* chemokine receptor 1 (*Cx3cr1*) was found in monocytes and resident macrophages in all mouse tissues [160]. *Cx3cr1-Cre* mice were generated and used for the conditional expression of the diphtheria toxin receptor in testis macrophages for further excision, despite no direct evidence of a cKO event, with an efficiency of approximately 95%, indicating the effectiveness of *Cx3cr1-Cre* in the macrophage population [160,161]. However, *Cx3cr1* is extensively expressed in macrophages and monocytes; therefore, potential disturbances cannot be ignored.

Evidence suggests that a *Cre* line is generated, particularly targeting endothelial cells of the testis. *Tie2-Cre* (Strain #:008863) is localized in endothelial cells in the testis [19,162]. O'Hara et al. performed further research by applying *Tie2-Cre* to inactivate androgen receptors in testicular vascular endothelial cells [163]. Additionally, *Cre* lines that have undergone careful validation in other tissues are expected to remove the targets of interest in endothelial cells of the testis, such as *Cdh5-Cre* [164] and *Pdgfb-iCreER^{T2}* [165]. Concerns regarding *Cre*-engineered mouse strains, especially macrophages, have been widely reported, with *LysM-Cre* and *hCD68-CreER^{T2}* being the common methodologies [166]. *LysM-Cre* is prominently expressed in major myeloid lineage cell types, such as monocytes and neutrophils (Figure 2), whereas *hCD68-CreER^{T2}* primarily targets tissue-resident macrophages and is inducible by tamoxifen [167]. *LysM-Cre* was utilized to generate myeloid-specific ubiquitin-specific protease 2 (*USP2*) cKO mice, revealing the necessity of macrophage *USP2* for sperm physiological functions, including motility, capacitation, and hyperactivation [168]. Despite reports of the recombination efficiency of *Cre*, evidence supporting its ability to eliminate specific genes in testicular macrophages remains lacking. Other cell types identified through single-cell sequencing in the testes, such as T cells, mesenchymal (stromal) cells, and tenocytes [151–153], have been poorly studied in terms of their regulation of germ cell development, and a detailed description of the cKO strategy is not provided.

7. *Cre* Models for Epididymis

Sperm exhibit progressive motility and fertilization properties during transit in the epididymis, a highly convoluted duct comprising four main anatomical parts as follows: the initial segment (IS), caput, corpus, and cauda, each with distinct regional functions and characteristics [169]. The microenvironment of the epididymal lumen undergoes various changes during sperm transportation, with a large number of ions, proteins, and miRNAs absorbed or released into the lumen fluid [169]. Approximately 40% of male idiopathic infertility cases are associated with defects in sperm maturation, underscoring the importance of the epididymal function in sperm maturation [170]. Although assisted reproductive techniques (ART) contribute to improving sperm maturation status, reproductive risks related to artificial interventions are increasingly emphasized [170]. It is necessary to elucidate the mechanism of sperm maturation in the epididymis and ameliorate male reproductive

performance with minimal external interventions. To date, multiple *Cre*-engineered mouse models have been employed in many investigations of targets in the epididymal segments.

7.1. *Defb41-iCre*

DEFB41, containing 62 amino acids, is a specific beta-defensin, primarily localized in the epithelial cells of the initial segment and caput, with weak signals in the prostate, corpus, and pancreas [171]. The initial expression was detected at 7–14 DPP, peaked at 25 DPP, and remained stable after 40 DPP [172]. The *Defb41-iCre* KI mouse line was generated using the red/ET recombination approach, and the first exon of *Defb41* was inserted with *Cre* recombinase constructed in a BAC [172]. Björkgren et al. showed that *Defb41* ablation in the epididymis altered sperm progressive motility and the ability to bind to the oocyte, whereas sperm morphology and count were unaffected in the homozygous *Defb41^{iCre/iCre}* mouse strain [172]. Consequently, heterozygous *Defb41^{iCre/+}* mice were used as a cKO tool line to detect *Dicer1* physiological properties in the initial segment and caput by the progeny from *Dicer1^{fl/fl}; Defb41^{iCre/+}* mice [173,174].

7.2. *Rnase10-Cre*

The initial expression of *Rnase10*, coinciding with IS differentiation, was detected at approximately 17 DPP [175]. The disruption of proximal proteins encoded by *Rnase10* in the mouse epididymis is associated with a penetrating defect in the zona pellucida, rendering sperm unable to pass through the female uterotubal junction district [176]. The *Rnase10-iCre* line was established by introducing the *iCre-NeoR* cassette into the *Rnase10* translation initiation locus in the first eight nucleotides of exon 2 [177]. The androgen receptor (AR) was inactivated by the *Rnase10-iCre* mice mating with *AR^{fl/fl}* homozygous females, validating the critical role of AR in the function and development of IS [177].

7.3. *Crisp4-Cre*

CRISP4 is a cysteine-rich secretory protein (CRISP) that is highly expressed in murine principal cells in the epididymal epithelium, with its transcripts most abundantly present in the caput and corpus and few signals in the thymus and spleen [178,179]. CRISP4 has also been detected in epididymosomes and seminal plasma [180] and is strongly associated with sperm maturation during the epididymal transport process [181]. CRISP4 inactivation causes the failure of protein tyrosine phosphorylation and the acrosome reaction induced by progesterone in the capacitation process [182] and is incapable of fertilization with zona pellucida-intact eggs, probably due to the calcium channel TRPM8 defect and failure to regulate the acrosome reaction [181]. *Crisp4-iCre* KI mice were generated by inserting the *iCre*-neomycin phosphotransferase cassette into the third *Crisp4* exon locus before the initiation codon, resulting in a transcription frameshift. The homozygous *iCre*-recombinase line acts as a *Crisp4*-deficient model, and the heterozygous mouse model can be used to excise targets of interest in the epididymis [180]. *Crisp4-iCre* is expressed in the epididymis at day 20 of postnatal development, and its level increases with age [180]. The specificity of the *Crisp4-iCre* recombination event performed by *Crisp4^{+/-}/Z/RED⁺* and *Crisp4^{+/-}/Runx1^{fl/+}* transgenic mice was expressed in the whole epididymis tissue and in proximal epididymis without signals in other tissues detected, respectively [180], indicating that *Crisp4-iCre* is capable of ablating targets in vivo.

7.4. *Lipocalin-Cre*

mE-RABP (*Lcn5*), mEP17 (*Lcn8*), and lipocalin 9 (*Lcn9*), defined in the lipocalin family by phylogenetic analysis, are murine secretory proteins localized in the epididymis [183]. *Lcn5* is synthesized in principal cells residing in the middle/distal caput regions and is initially secreted from 30 DPP, with a gradual increase to 60 DPP [184]. *Lcn8* and *Lcn9* are positioned in the IS with similar expression patterns and are expressed at 21 DPP during postnatal development, depending on testicular factor regulation [183,185]. Spermatogenesis and fertility were normal conditions after *Lcn8* or *Lcn9* inactivation in the epididymis,

while *Lcn8* ablation caused an increased teratospermia rate, sperm motility, and acrosome reaction frequency deficiency, indicating its indispensable role in sperm maturation [186]. Lipocalin family genes are highly conserved and show homology among subtypes, with the probability of functional overlap in a physiological manner. The transgenic lines in *Lcn5*, *Lcn6*, *Lcn8*, and *Lcn10* were knocked out simultaneously, or *Lcn5*, *Lcn6*, *Lcn8*, *Lcn10*, and *Lcn9*, when silenced synchronously, showed subfertility and infertility in most cases [187].

The *Lcn5-Cre* transgenic mice were established by Xie et al. using the *Cre/LoxP* system, where *Cre* activity was regulated by the *Lcn5* promoter (1.8 kb). Initially, *Cre* catalytic activity was observed at 30 DPP, showing high specificity in middle or distal caput principal cells when crossed with the reporter strain mT/mG or with the *Aip1^{fl/+}* mouse line. The recombination efficiency was statistically significant at 28.9% [188]. A tamoxifen-sensitive *Lcn5-CreER^{T2}* transgenic line was generated by the same group. *Cre* activity was also highly restricted in the caput epididymis by tamoxifen induction in a time- and dose-dependent manner, providing an approach for the further analysis of the spatiotemporal functions of target genes in the caput epididymis [189]. *Lcn8-Cre* or *Lcn9-Cre* mice were generated by the insertion of the *NLS-Cre-polyA* or *2A-NLS-Cre* cassette into the *Lcn8* or *Lcn9* promoters, respectively, using CRISPR/Cas9 technology; *Cre* expression led to the loss of *Lcn8* and *Lcn9*. *Lcn8-Cre* and *Lcn9-Cre* activity is specially confined to the principal cells of the IS, without reproductive disorders, in adult male mice [190,191]. Novel *Lcn8-Cre* and *Lcn9-Cre* models can be used to conduct functional gene studies that are specific to IS segments (Figure 2). However, transgenic mouse models with *Cre* bioactivity in the epididymal cauda are still lacking; thus, generating more recombinant mouse lines, particularly those with silencing targets in the epididymis, is necessary.

8. The *Cre* Models Generated for the Prostate, Seminal Vesicle, and Seminiferous Duct

The prostate is an adnexal gland of the male genitourinary system, primarily comprising the stroma and epithelium. Prostatic fluid is secreted by the prostate epithelial compartment and occupies approximately 1/5 to 1/3 of the volume of ejaculated semen. It contributes to sperm motility, the clotting cycle, and semen liquefaction [192]. *Cre* expression under the regulation of the promoter derived from the prostate-specific probasin (*ARR2PB*) of rats and *ARR2PB-Cre* (Strain #:026662) catalytic activity was detected predominantly in all lobes of the mouse prostate. The highest signals were observed in the lateral lobes driving androgen-dependent transcription events, while *Cre* activity was least visible in the anterior and dorsal lobes. The further functional characterization of *ARR2PB-Cre* was carried out by selectively removing *RXR α* from the mouse prostate and avoiding the embryonic lethality caused by *RXR α* global KO [193]. In addition, Jin et al. generated an *ARR2PB β -Cre* transgenic mouse line (Strain #023325), showing uniform expression across all lobes of the prostate as well as in the ductus deferens and seminal vesicles. This model exhibited higher efficiency in interfering with gene activity in target tissues [194]. *ARR2PB β -Cre* mice are a valuable tool for genetic-based investigations of the prostate, seminal vesicles, and ductus deferens (Figure 2).

9. Conclusions and Perspective

An orchestrated series of events, mainly involving PGC development, SSC maintenance, spermatogenesis, sperm maturation, and ejaculation, ensures male fertility under normal conditions depending on certain genetic expressions during different physiological phases. Conventional KOs often lead to embryonic or perinatal lethality, particularly in homozygotes, and may result in unpredictable impacts on other organs with abnormal physiology. The increasing use of *Cre* recombination lines highlights the validity of the *Cre/LoxP* system as a valid molecular genetics approach for reproductive research. In this study, we summarized the *Cre* mouse lines used to investigate gene behavior during various processes related to germ cell biology and sperm physiological function. We also addressed existing issues such as unstable efficiency, global KO, the ectopic expression of *Cre* activity, and strong maternal effects. The unpredictable expression pattern of *Cre* in the

testes may be attributed to chromatin compaction and rearrangement during meiosis, as well as the randomness of insertion sites and cassette defects in traditional gene recombination methods. As early as 2013, the CRISPR/Cas9 system was used to mutate the mouse genome, resulting in a genetically disrupted mouse line that was achieved faster and at lower costs [13]. CRISPR/Cas9 can act on multiple loci simultaneously and contribute to investigating the combined effects of genes on reproduction or establish connections among targeted genes in the fertility process [195,196]. Moreover, random insertions and uncontrolled gene copies caused by transgenic steps in conventional recombination are avoided in the CRISPR/Cas9 system [197]. In this review, we summarized several gene-disrupted mouse lines edited by the CRISPR/Cas9 approach, including *Ddx4^{iCre}* [15], *Ddx4^{em1(CreERT2)Utr}* [20], *Stra8^{P2A-Cre}* [43], *Acrv1-iCre* [106], *Lcn8-Cre* and *Lcn9-Cre* [190,191], which showed higher specificity, efficiency, and the lower occurrence of global KO events. Other recommendations are as follows: 1. Combining multiple inducible *Cre* lines can help inactivate target genes localized in distinct regions of the epididymis, as some genes are distributed throughout the entire epididymis without regional differences, and a clear phenotype may not be visible under gene disruption in a single segment. 2. The strict control of *Cre-LoxP* can be strengthened by combining it with the *Dre-Rox* system, making lineage tracing more precise and minimizing the non-determinate effects of *Cre* catalytic activity on certain cells [198]. Thus, a more credible and accurate *in vivo* study of the cell lineage from the male reproductive system is warranted by this novel technology, as it greatly reduces the nonspecific recombination of the conventional *Cre-LoxP* system. 3. There is a demand to generate new homozygous *Cre* lines for gene recombination in spermatids with higher efficiency and stable outcomes, and it is worth considering the expansion of *Cre* models for the corpus and cauda epididymis.

Overall, as a large number of genes play a vital role during the male reproductive process, more mouse tool models can be established and be made available for detailed descriptions of genes to reveal the male reproductive mystery at the genetic level.

Author Contributions: X.Z. designed and conceived the review. P.D. wrote the manuscript. C.C. and M.L. performed schematic diagram drawing. C.M., S.D. and H.C. revised the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This study was funded by the Basic Science Research Program of Nantong (JC22022086) funded by the Nantong Science and Technology Bureau.

Conflicts of Interest: The authors declare no conflicts of interest.

References

1. Karimova, M.; Abi-Ghanem, J.; Berger, N.; Surendranath, V.; Pisabarro, M.T.; Buchholz, F. Vika/vox, a novel efficient and specific Cre/loxP-like site-specific recombination system. *Nucleic Acids Res.* **2013**, *41*, e37. [[CrossRef](#)] [[PubMed](#)]
2. Karimova, M.; Baker, O.; Camgoz, A.; Naumann, R.; Buchholz, F.; Anastassiadis, K. A single reporter mouse line for Vika, Flp, Dre, and Cre-recombination. *Mater. Sci. Eng. A* **2018**, *8*, 14453. [[CrossRef](#)] [[PubMed](#)]
3. Nakayama, M. VCre/VloxP and SCre/SloxP as Reliable Site-Specific Recombination Systems for Genome Engineering. *Methods Mol. Biol.* **2023**, *2637*, 161–180. [[CrossRef](#)]
4. Takeuchi, T.; Nomura, T.; Tsujita, M.; Suzuki, M.; Fuse, T.; Mori, H.; Mishina, M. Flp recombinase transgenic mice of C57BL/6 strain for conditional gene targeting. *Biochem. Biophys. Res. Commun.* **2002**, *293*, 953–957. [[CrossRef](#)] [[PubMed](#)]
5. Suzuki, E.; Nakayama, M. VCre/VloxP and SCre/SloxP: New site-specific recombination systems for genome engineering. *Nucleic Acids Res.* **2011**, *39*, e49. [[CrossRef](#)] [[PubMed](#)]
6. Sauer, B.; Henderson, N. Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1. *Proc. Natl. Acad. Sci. USA* **1988**, *85*, 5166–5170. [[CrossRef](#)] [[PubMed](#)]
7. Sauer, B.; Henderson, N. Cre-stimulated recombination at loxP-containing DNA sequences placed into the mammalian genome. *Nucleic Acids Res.* **1989**, *17*, 147–161. [[CrossRef](#)] [[PubMed](#)]
8. Wang, X. Cre transgenic mouse lines. *Transgenesis Tech. Princ. Protoc.* **2009**, *561*, 265–273. [[CrossRef](#)] [[PubMed](#)]
9. Rashbrook, V.S.; Brash, J.T.; Ruhrberg, C. Cre toxicity in mouse models of cardiovascular physiology and disease. *Nat. Cardiovasc. Res.* **2022**, *1*, 806–816. [[CrossRef](#)]
10. Garrick, D.; Fiering, S.; Martin, D.I.; Whitelaw, E. Repeat-induced gene silencing in mammals. *Nat. Genet.* **1998**, *18*, 56–59. [[CrossRef](#)]

11. Gurumurthy, C.B.; Saunders, T.L.; Ohtsuka, M. Designing and generating a mouse model: Frequently asked questions. *J. Biomed. Res.* **2021**, *35*, 76. [[CrossRef](#)] [[PubMed](#)]
12. Gupta, D.; Bhattacharjee, O.; Mandal, D.; Sen, M.K.; Dey, D.; Dasgupta, A.; Kazi, T.A.; Gupta, R.; Sinharoy, S.; Acharya, K.; et al. CRISPR-Cas9 system: A new-fangled dawn in gene editing. *Life Sci.* **2019**, *232*, 116636. [[CrossRef](#)] [[PubMed](#)]
13. Young, S.A.; Aitken, R.J.; Ikawa, M. Advantages of using the CRISPR/Cas9 system of genome editing to investigate male reproductive mechanisms using mouse models. *Asian J. Androl.* **2015**, *17*, 623. [[PubMed](#)]
14. Neto, F.T.L.; Bach, P.V.; Najari, B.B.; Li, P.S.; Goldstein, M. Spermatogenesis in humans and its affecting factors. *Semin. Cell Dev. Biol.* **2016**, *59*, 10–26. [[CrossRef](#)] [[PubMed](#)]
15. Burnet, G.; Feng, C.A. Generation and characterization of a Ddx4-iCre transgenic line for deletion in the germline beginning at genital ridge colonization. *Genesis* **2023**, *61*, e23511. [[CrossRef](#)] [[PubMed](#)]
16. Vidal, F.; Sage, J.; Cuzin, F.; Rassoulzadegan, M. Cre expression in primary spermatocytes: A tool for genetic engineering of the germ line. *Mol. Reprod. Dev.* **1998**, *51*, 274–280. [[CrossRef](#)]
17. O’Gorman, S.; Dagenais, N.A.; Qian, M.; Marchuk, Y. Protamine-Cre recombinase transgenes efficiently recombine target sequences in the male germ line of mice, but not in embryonic stem cells. *Proc. Natl. Acad. Sci. USA* **1997**, *94*, 14602–14607. [[CrossRef](#)] [[PubMed](#)]
18. Hammond, S.S.; Matin, A. Tools for the genetic analysis of germ cells. *Genesis* **2009**, *47*, 617–627. [[CrossRef](#)]
19. Smith, L. Good planning and serendipity: Exploiting the Cre/Lox system in the testis. *Reproduction* **2011**, *141*, 151–161. [[CrossRef](#)]
20. Le, H.T.; Hasegawa, Y.; Daitoku, Y.; Kato, K.; Miznuo-Iijima, S.; Dinh, T.T.H.; Kuba, Y.; Osawa, Y.; Mikami, N.; Morimoto, K.; et al. Generation of B6-Ddx4(em1(CreERT2)Utr), a novel CreERT2 knock-in line, for germ cell lineage by CRISPR/Cas9. *Genesis* **2020**, *58*, e23367. [[CrossRef](#)]
21. Sheldon, C.; Kessinger, C.W.; Sun, Y.; Kontaridis, M.I.; Ma, Q.Y.; Hammoud, S.S.; Gao, Z.B.; Zhang, H.; Lin, Z.Q. Myh6 promoter-driven Cre recombinase excises floxed DNA fragments in a subset of male germline cells. *J. Mol. Cell Cardiol.* **2023**, *175*, 62–66. [[CrossRef](#)] [[PubMed](#)]
22. Rassoulzadegan, M.; Magliano, M.; Cuzin, F. Transvection effects involving DNA methylation during meiosis in the mouse. *EMBO J.* **2002**, *21*, 440–450. [[CrossRef](#)] [[PubMed](#)]
23. Batista, F.; Lu, L.; Williams, S.A.; Stanley, P. Complex N-glycans are essential, but core 1 and 2 mucin O-glycans, O-fucose glycans, and NOTCH1 are dispensable, for mammalian spermatogenesis. *Biol. Reprod.* **2012**, *86*, 179. [[CrossRef](#)] [[PubMed](#)]
24. Fan, J.; Campioli, E.; Sottas, C.; Zirkin, B.; Papadopoulos, V. Amhr2-Cre-Mediated Global Tspo Knockout. *J. Endocr. Soc.* **2020**, *4*, bvaa001. [[CrossRef](#)] [[PubMed](#)]
25. Xu, C.; Cao, Y.; Bao, J. Building RNA-protein germ granules: Insights from the multifaceted functions of DEAD-box helicase Vasa/Ddx4 in germline development. *Cell Mol. Life Sci.* **2022**, *79*, 4. [[CrossRef](#)] [[PubMed](#)]
26. Cardoso-Moreira, M.; Halbert, J.; Valloton, D.; Velten, B.; Chen, C.; Shao, Y.; Liechti, A.; Ascensão, K.; Rummel, C.; Ovchinnikova, S.; et al. Gene expression across mammalian organ development. *Nature* **2019**, *571*, 505–509. [[CrossRef](#)] [[PubMed](#)]
27. Tanaka, S.S.; Toyooka, Y.; Akasu, R.; Katoh-Fukui, Y.; Nakahara, Y.; Suzuki, R.; Yokoyama, M.; Noce, T. The mouse homolog of Drosophila Vasa is required for the development of male germ cells. *Genes Dev.* **2000**, *14*, 841–853. [[CrossRef](#)]
28. Toyooka, Y.; Tsunekawa, N.; Takahashi, Y.; Matsui, Y.; Satoh, M.; Noce, T. Expression and intracellular localization of mouse Vasa-homologue protein during germ cell development. *Mech. Dev.* **2000**, *93*, 139–149. [[CrossRef](#)] [[PubMed](#)]
29. Song, K.; Ma, W.; Huang, C.; Ding, J.; Cui, D.; Zhang, M. Expression Pattern of Mouse Vasa Homologue (MVH) in the Ovaries of C57BL/6 Female Mice. *Med. Sci. Monit. Int. Med. J. Exp. Clin. Res.* **2016**, *22*, 2656–2663. [[CrossRef](#)]
30. Gallardo, T.; Shirley, L.; John, G.B.; Castrillon, D.H. Generation of a germ cell-specific mouse transgenic Cre line, Vasa-Cre. *Genesis* **2007**, *45*, 413–417. [[CrossRef](#)]
31. Hayashi, S.; McMahon, A.P. Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: A tool for temporally regulated gene activation/inactivation in the mouse. *Dev. Biol.* **2002**, *244*, 305–318. [[CrossRef](#)] [[PubMed](#)]
32. Feil, R.; Brocard, J.; Mascres, B.; LeMeur, M.; Metzger, D.; Chambon, P. Ligand-activated site-specific recombination in mice. *Proc. Natl. Acad. Sci. USA* **1996**, *93*, 10887–10890. [[CrossRef](#)] [[PubMed](#)]
33. Metzger, D.; Clifford, J.; Chiba, H.; Chambon, P. Conditional site-specific recombination in mammalian cells using a ligand-dependent chimeric Cre recombinase. *Proc. Natl. Acad. Sci. USA* **1995**, *92*, 6991–6995. [[CrossRef](#)] [[PubMed](#)]
34. Feil, R.; Wagner, J.; Metzger, D.; Chambon, P. Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains. *Biochem. Biophys. Res. Commun.* **1997**, *237*, 752–757. [[CrossRef](#)] [[PubMed](#)]
35. Anderson, E.L.; Baltus, A.E.; Roepers-Gajadien, H.L.; Hassold, T.J.; de Rooij, D.G.; van Pelt, A.M.; Page, D.C. Stra8 and its inducer, retinoic acid, regulate meiotic initiation in both spermatogenesis and oogenesis in mice. *Proc. Natl. Acad. Sci. USA* **2008**, *105*, 14976–14980. [[CrossRef](#)] [[PubMed](#)]
36. Soh, Y.Q.; Junker, J.P.; Gill, M.E.; Mueller, J.L.; van Oudenaarden, A.; Page, D.C. A Gene Regulatory Program for Meiotic Prophase in the Fetal Ovary. *PLoS Genet.* **2015**, *11*, e1005531. [[CrossRef](#)] [[PubMed](#)]
37. Ma, H.T.; Niu, C.M.; Xia, J.; Shen, X.Y.; Xia, M.M.; Hu, Y.Q.; Zheng, Y. Stimulated by retinoic acid gene 8 (Stra8) plays important roles in many stages of spermatogenesis. *Asian J. Androl.* **2018**, *20*, 479–487. [[CrossRef](#)] [[PubMed](#)]
38. Sadate-Ngatchou, P.I.; Payne, C.J.; Dearth, A.T.; Braun, R.E. Cre recombinase activity specific to postnatal, premeiotic male germ cells in transgenic mice. *Genesis* **2008**, *46*, 738–742. [[CrossRef](#)]

39. Bao, J.; Ma, H.Y.; Schuster, A.; Lin, Y.M.; Yan, W. Incomplete cre-mediated excision leads to phenotypic differences between Stra8-iCre; Mov10l1(lox/lox) and Stra8-iCre; Mov10l1(lox/ Δ) mice. *Genesis* **2013**, *51*, 481–490. [[CrossRef](#)]
40. Blanco, M.; El Khattabi, L. DOT1L regulates chromatin reorganization and gene expression during sperm differentiation. *EMBO Rep.* **2023**, *24*, e56316. [[CrossRef](#)]
41. Feng, C.W.; Burnet, G. Identification of regulatory elements required for Stra8 expression in fetal ovarian germ cells of the mouse. *Development* **2021**, *148*, 194977. [[CrossRef](#)] [[PubMed](#)]
42. Lin, Z.; Hsu, P.J.; Xing, X.; Fang, J.; Lu, Z.; Zou, Q.; Zhang, K.J.; Zhang, X.; Zhou, Y.; Zhang, T.; et al. Methyl3-/Methyl14-mediated mRNA N(6)-methyladenosine modulates murine spermatogenesis. *Cell Res.* **2017**, *27*, 1216–1230. [[CrossRef](#)] [[PubMed](#)]
43. Ahmed, A.A.; Salas, E.; Lanza, D.G.; Heaney, J.D.; Pangas, S.A. Generation of a novel Stra8-driven Cre recombinase strain for use in pre-meiotic germ cells in mice. *Biol. Reprod.* **2023**, *109*, 184–191. [[CrossRef](#)] [[PubMed](#)]
44. Jiang, X.; Cheng, Y.; Zhu, Y.; Xu, C.; Li, Q.; Xing, X.; Li, W.; Zou, J.; Meng, L.; Azhar, M.; et al. Maternal NAT10 orchestrates oocyte meiotic cell-cycle progression and maturation in mice. *Nat. Commun.* **2023**, *14*, 3729. [[CrossRef](#)] [[PubMed](#)]
45. Lemaire-Vieille, C.; Schulze, T.; Podevin-Dimster, V.; Follet, J.; Bailly, Y.; Blanquet-Grossard, F.; Decavel, J.-P.; Heinen, E.; Cesbron, J.-Y. Epithelial and endothelial expression of the green fluorescent protein reporter gene under the control of bovine prion protein (PrP) gene regulatory sequences in transgenic mice. *Proc. Natl. Acad. Sci. USA* **2000**, *97*, 5422–5427. [[CrossRef](#)]
46. Weber, P.; Schuler, M.; Gérard, C.; Mark, M.; Metzger, D.; Chambon, P. Temporally controlled site-specific mutagenesis in the germ cell lineage of the mouse testis. *Biol. Reprod.* **2003**, *68*, 553–559. [[CrossRef](#)] [[PubMed](#)]
47. Saitou, M.; Barton, S.C.; Surani, M.A. A molecular programme for the specification of germ cell fate in mice. *Nature* **2002**, *418*, 293–300. [[CrossRef](#)] [[PubMed](#)]
48. Sato, M.; Kimura, T.; Kurokawa, K.; Fujita, Y.; Abe, K.; Masuhara, M.; Yasunaga, T.; Ryo, A.; Yamamoto, M.; Nakano, T. Identification of PGC7, a new gene expressed specifically in preimplantation embryos and germ cells. *Mech. Dev.* **2002**, *113*, 91–94. [[CrossRef](#)]
49. Payer, B.; Saitou, M.; Barton, S.C.; Thresher, R.; Dixon, J.P.C.; Zahn, D.; Colledge, W.H.; Carlton, M.B.L.; Nakano, T.; Surani, M.A. is a maternal effect gene required for normal early development in mice. *Curr. Biol.* **2003**, *13*, 2110–2117. [[CrossRef](#)]
50. Hirota, T.; Ohta, H.; Shigeta, M.; Niwa, H.; Saitou, M. Drug-inducible gene recombination by the Dppa3-MER Cre MER transgene in the developmental cycle of the germ cell lineage in mice. *Biol. Reprod.* **2011**, *85*, 367–377. [[CrossRef](#)]
51. Thelen, B.; Schipperges, V.; Knörlein, P.; Hummel, J.F.; Arnold, F.; Kupferschmid, L.; Klose, C.S.N.; Arnold, S.J.; Boerries, M.; Tanriver, Y. Eomes is sufficient to regulate IL-10 expression and cytotoxic effector molecules in murine CD4⁺ T cells. *Front. Immunol.* **2023**, *14*, 1058267. [[CrossRef](#)] [[PubMed](#)]
52. Russ, A.P.; Wattler, S.; Colledge, W.H.; Aparicio, S.A.; Carlton, M.B.; Pearce, J.J.; Barton, S.C.; Surani, M.A.; Ryan, K.; Nehls, M.C.; et al. Eomesodermin is required for mouse trophoblast development and mesoderm formation. *Nature* **2000**, *404*, 95–99. [[CrossRef](#)]
53. Raab, S.; Klingenstein, M.; Möller, A.; Illing, A.; Tomic, J.; Breunig, M.; Kualess, G.; Linta, L.; Seufferlein, T.; Arnold, S.J. Reprogramming to pluripotency does not require transition through a primitive streak-like state. *Sci. Rep.* **2017**, *7*, 16543. [[CrossRef](#)]
54. Sharma, M.; Srivastava, A.; Fairfield, H.E.; Bergstrom, D.; Flynn, W.F.; Braun, R.E. Identification of EOMES-expressing spermatogonial stem cells and their regulation by PLZF. *Elife* **2019**, *8*, e43352. [[CrossRef](#)]
55. Legrand, J.M.; Hobbs, R.M. Defining Gene Function in Spermatogonial Stem Cells Through Conditional Knockout Approaches. In *Spermatogonial Stem Cells: Methods and Protocols*; Springer: Berlin/Heidelberg, Germany, 2023; pp. 261–307.
56. Sommer, L.; Ma, Q.; Anderson, D.J.J.M. Neuroscience, *C. neurogenins*, a novel family of atonal-related bHLH transcription factors, are putative mammalian neuronal determination genes that reveal progenitor cell heterogeneity in the developing CNS and PNS. *Mol. Cell. Neurosci.* **1996**, *8*, 221–241. [[CrossRef](#)]
57. Yoshida, S.; Takakura, A.; Ohbo, K.; Abe, K.; Wakabayashi, J.; Yamamoto, M.; Suda, T.; Nabeshima, Y.I. Neurogenin3 delineates the earliest stages of spermatogenesis in the mouse testis. *Dev. Biol.* **2004**, *269*, 447–458. [[CrossRef](#)] [[PubMed](#)]
58. Sada, A.; Hasegawa, K.; Pin, P.H.; Saga, Y. NANOS2 acts downstream of glial cell line-derived neurotrophic factor signaling to suppress differentiation of spermatogonial stem cells. *J. Stem Cells* **2012**, *30*, 280–291. [[CrossRef](#)]
59. Yoshida, S.; Sukeno, M.; Nakagawa, T.; Ohbo, K.; Nagamatsu, G.; Suda, T.; Nabeshima, Y.-i. The first round of mouse spermatogenesis is a distinctive program that lacks the self-renewing spermatogonia stage. *Development* **2006**, *133*, 1495–1505. [[CrossRef](#)]
60. Schonhoff, S.E.; Giel-Moloney, M.; Leiter, A.B. Neurogenin 3-expressing progenitor cells in the gastrointestinal tract differentiate into both endocrine and non-endocrine cell types. *Dev. Biol.* **2004**, *270*, 443–454. [[CrossRef](#)] [[PubMed](#)]
61. Korhonen, H.M.; Meikar, O.; Yadav, R.P.; Papaioannou, M.D.; Romero, Y.; Da Ros, M.; Herrera, P.L.; Toppari, J.; Nef, S.; Kotaja, N. Dicer is required for haploid male germ cell differentiation in mice. *PLoS ONE* **2011**, *6*, e24821. [[CrossRef](#)]
62. Zheng, K.; Wang, P.J. Blockade of pachytene piRNA biogenesis reveals a novel requirement for maintaining post-meiotic germline genome integrity. *PLoS Genet.* **2012**, *8*, e1003038. [[CrossRef](#)]
63. Bai, S.; Cheng, L.; Zhang, Y.; Zhu, C.; Zhu, Z.; Zhu, R.; Cheng, C.Y.; Ye, L.; Zheng, K. A germline-specific role for the mTORC2 component Rictor in maintaining spermatogonial differentiation and intercellular adhesion in mouse testis. *Mol. Hum. Reprod.* **2018**, *24*, 244–259. [[CrossRef](#)] [[PubMed](#)]
64. Jin, C.; Zhang, Y.; Wang, Z.-P.; Wang, X.-X.; Sun, T.-C.; Li, X.-Y.; Tang, J.-X.; Cheng, J.-M.; Li, J.; Chen, S.-R. EZH2 deletion promotes spermatogonial differentiation and apoptosis. *Reproduction* **2017**, *154*, 615–625. [[CrossRef](#)] [[PubMed](#)]

65. Evans, E.; Hogarth, C.; Mitchell, D.; Griswold, M. Riding the spermatogenic wave: Profiling gene expression within neonatal germ and sertoli cells during a synchronized initial wave of spermatogenesis in mice. *Biol. Reprod.* **2014**, *90*, 108. [[CrossRef](#)] [[PubMed](#)]
66. Lomelí, H.; Ramos-Mejía, V.; Gertsenstein, M.; Lobe, C.G.; Nagy, A. Targeted insertion of Cre recombinase into the TNAP gene: Excision in primordial germ cells. *Genesis* **2000**, *26*, 116–117. [[CrossRef](#)]
67. Suzuki, H.; Tsuda, M.; Kiso, M.; Saga, Y. Nanos3 maintains the germ cell lineage in the mouse by suppressing both Bax-dependent and -independent apoptotic pathways. *Dev. Biol.* **2008**, *318*, 133–142. [[CrossRef](#)]
68. Ohinata, Y.; Payer, B.; O'Carroll, D.; Ancelin, K.; Ono, Y.; Sano, M.; Barton, S.C.; Obukhanych, T.; Nussenzweig, M.; Tarakhovsky, A.; et al. Blimp1 is a critical determinant of the germ cell lineage in mice. *Nature* **2005**, *436*, 207–213. [[CrossRef](#)]
69. Chang, D.H.; Calame, K.L. The dynamic expression pattern of B lymphocyte induced maturation protein-1 (Blimp-1) during mouse embryonic development. *Mech. Dev.* **2002**, *117*, 305–309. [[CrossRef](#)] [[PubMed](#)]
70. Robertson, E.J.; Charatsi, I.; Joyner, C.J.; Koonce, C.H.; Morgan, M.; Islam, A.; Paterson, C.; Lejsek, E.; Arnold, S.J.; Kallies, A.; et al. Blimp1 regulates development of the posterior forelimb, caudal pharyngeal arches, heart and sensory vibrissae in mice. *Development* **2007**, *134*, 4335–4345. [[CrossRef](#)]
71. Legrand, J.M.; Chan, A.-L.; La, H.M.; Rossello, F.J.; Änkö, M.-L.; Fuller-Pace, F.V.; Hobbs, R.M. DDX5 plays essential transcriptional and post-transcriptional roles in the maintenance and function of spermatogonia. *Nat. Commun.* **2019**, *10*, 2278. [[CrossRef](#)]
72. Matson, C.K.; Murphy, M.W.; Griswold, M.D.; Yoshida, S.; Bardwell, V.J.; Zarkower, D. The mammalian doublesex homolog DMRT1 is a transcriptional gatekeeper that controls the mitosis versus meiosis decision in male germ cells. *Dev. Cell* **2010**, *19*, 612–624. [[CrossRef](#)] [[PubMed](#)]
73. Tomizawa, S.-i.; Kobayashi, Y.; Shirakawa, T.; Watanabe, K.; Mizoguchi, K.; Hoshi, I.; Nakajima, K.; Nakabayashi, J.; Singh, S.; Dahl, A. Kmt2b conveys monoallelic and bivalent H3K4me3 in mouse spermatogonial stem cells at germline and embryonic promoters. *Development* **2018**, *145*, dev169102. [[CrossRef](#)] [[PubMed](#)]
74. Ferreira, M.; Boens, S.; Winkler, C.; Szekér, K.; Verbinnen, I.; Van Eynde, A.; Fardilha, M.; Bollen, M. The protein phosphatase 1 regulator NIPPI1 is essential for mammalian spermatogenesis. *Sci. Rep.* **2017**, *7*, 13364. [[CrossRef](#)] [[PubMed](#)]
75. López, I.P.; Rodríguez-de la Rosa, L.; Pais, R.S.; Pineiro-Hermida, S.; Torrens, R.; Contreras, J.; Varela-Nieto, I.; Pichel, J.G. Differential organ phenotypes after postnatal Igf1r gene conditional deletion induced by tamoxifen in UBC-CreERT2; Igf1r fl/fl double transgenic mice. *Transgenic Res.* **2015**, *24*, 279–294. [[CrossRef](#)] [[PubMed](#)]
76. Zhang, Y.; Riesterer, C.; Ayral, A.-M.; Sablitzky, F.; Littlewood, T.D.; Reth, M. Inducible site-directed recombination in mouse embryonic stem cells. *Nucleic Acids Res.* **1996**, *24*, 543–548. [[CrossRef](#)] [[PubMed](#)]
77. Schöler, H.; Dressler, G.R.; Balling, R.; Rohdewohld, H.; Gruss, P. Oct-4: A germline-specific transcription factor mapping to the mouse t-complex. *EMBO J.* **1990**, *9*, 2185–2195. [[CrossRef](#)] [[PubMed](#)]
78. Zhang, T.; Oatley, J.; Bardwell, V.J.; Zarkower, D. DMRT1 is required for mouse spermatogonial stem cell maintenance and replenishment. *PLoS Genet.* **2016**, *12*, e1006293. [[CrossRef](#)] [[PubMed](#)]
79. Greder, L.V.; Gupta, S.; Li, S.N.; Abedin, M.J.; Sajini, A.; Segal, Y.; Slack, J.M.W.; Dutton, J.R. Brief Report: Analysis of Endogenous Oct4 Activation during Induced Pluripotent Stem Cell Reprogramming Using an Inducible Oct4 Lineage Label. *Stem Cells* **2012**, *30*, 2596–2601. [[CrossRef](#)] [[PubMed](#)]
80. Lengner, C.J.; Camargo, F.D.; Hochedlinger, K.; Welstead, G.G.; Zaidi, S.; Gokhale, S.; Scholer, H.R.; Tomilin, A.; Jaenisch, R. Oct4 expression is not required for mouse somatic stem cell self-renewal. *Cell Stem Cell* **2007**, *1*, 403–415. [[CrossRef](#)]
81. de Vries, F.A.; de Boer, E.; van den Bosch, M.; Baarends, W.M.; Ooms, M.; Yuan, L.; Liu, J.-G.; van Zeeland, A.A.; Heyting, C.; Pastink, A. Mouse Sycp1 functions in synaptonemal complex assembly, meiotic recombination, and XY body formation. *Genes Dev.* **2005**, *19*, 1376–1389. [[CrossRef](#)]
82. Chung, S.S.; Cuzin, F.; Rassoulzadegan, M.; Wolgemuth, D.J. Primary spermatocyte-specific Cre recombinase activity in transgenic mice. *Transgenic Res.* **2004**, *13*, 289–294. [[CrossRef](#)] [[PubMed](#)]
83. Rasoulpour, R.J.; Boekelheide, K. The Sycp1-Cre Transgenic Mouse and Male Germ Cell Inhibition of NF- κ B. *J. Androl.* **2006**, *27*, 729–733. [[CrossRef](#)] [[PubMed](#)]
84. Kraus, P.; Xing, X.; Lim, S.L.; Fun, M.E.; Sivakamasundari, V.; Yap, S.P.; Lee, H.; Karuturi, R.K.M.; Lufkin, T. Mouse strain specific gene expression differences for illumina microarray expression profiling in embryos. *BMC Res. Notes* **2012**, *5*, 232. [[CrossRef](#)]
85. Al-Soudy, A.S.; Nakanishi, T.; Mizuno, S.; Hasegawa, Y.; Shawki, H.H.; Katoh, M.C.; Basha, W.A.; Ibrahim, A.E.; El-Shemy, H.A.; Iseki, H.; et al. Germline recombination in a novel Cre transgenic line, Prl3b1-Cre mouse. *Genesis* **2016**, *54*, 389–397. [[CrossRef](#)]
86. Zou, Y.D.; Yao, H.H.; Li, J.C.; Zhang, K.; Li, Z.G. A novel WISP3 mutation in a Chinese patient with progressive pseudorheumatoid dysplasia. *QJM Mon. J. Assoc. Physicians* **2023**, *116*, 458–460. [[CrossRef](#)] [[PubMed](#)]
87. Nakamura, Y.; Cui, Y.; Fernando, C.; Kutz, W.E.; Warman, M.L. Normal growth and development in mice over-expressing the CCN family member WISP3. *J. Cell Commun. Signal.* **2009**, *3*, 105–113. [[CrossRef](#)]
88. Hann, S.; Kvenvold, L.; Newby, B.N.; Hong, M.; Warman, M.L. A Wisp3 Cre-knockin allele produces efficient recombination in spermatocytes during early prophase of meiosis I. *PLoS ONE* **2013**, *8*, e75116. [[CrossRef](#)] [[PubMed](#)]
89. Lester, W.C.; Johnson, T.; Hale, B.; Serra, N.; Elgart, B.; Wang, R.; Geyer, C.B.; Sperry, A.O. Aurora A Kinase (AURKA) is required for male germline maintenance and regulates sperm motility in the mouse. *Biol. Reprod.* **2021**, *105*, 1603–1616. [[CrossRef](#)]
90. Romanienko, P.J.; Camerini-Otero, R.D. The mouse Spo11 gene is required for meiotic chromosome synapsis. *Mol. Cell* **2000**, *6*, 975–987. [[CrossRef](#)]

91. Pellegrini, M.; Claps, G.; Orlova, V.V.; Barrios, F.; Dolci, S.; Geremia, R.; Rossi, P.; Rossi, G.; Arnold, B.; Chavakis, T.; et al. Targeted JAM-C deletion in germ cells by Spo11-controlled Cre recombinase. *J. Cell Sci.* **2011**, *124*, 91–99. [[CrossRef](#)]
92. Lyndaker, A.M.; Lim, P.X.; Mleczko, J.M.; Diggins, C.E.; Holloway, J.K.; Holmes, R.J.; Kan, R.; Schlafer, D.H.; Freire, R.; Cohen, P.E. Conditional inactivation of the DNA damage response gene Hus1 in mouse testis reveals separable roles for components of the RAD9-RAD1-HUS1 complex in meiotic chromosome maintenance. *PLoS Genet.* **2013**, *9*, e1003320. [[CrossRef](#)] [[PubMed](#)]
93. Faieta, M.; Di Cecca, S.; de Rooij, D.G.; Luchetti, A.; Murdocca, M.; Di Giacomo, M.; Di Siena, S.; Pellegrini, M.; Rossi, P.; Barchi, M. A surge of late-occurring meiotic double-strand breaks rescues synapsis abnormalities in spermatocytes of mice with hypomorphic expression of SPO11. *Chromosoma* **2016**, *125*, 189–203. [[CrossRef](#)] [[PubMed](#)]
94. Wellard, S.R.; Zhang, Y.; Shults, C.; Zhao, X.; McKay, M.; Murray, S.A.; Jordan, P.W. Overlapping roles for PLK1 and Aurora A during meiotic centrosome biogenesis in mouse spermatocytes. *EMBO Rep.* **2021**, *22*, e51023. [[CrossRef](#)] [[PubMed](#)]
95. Jakubiczka, S.; Schnieders, F.; Schmidtke, J. A bovine homologue of the human TSPY gene. *Genomics* **1993**, *17*, 732–735. [[CrossRef](#)] [[PubMed](#)]
96. Schubert, S.; Dechend, F.; Skawran, B.; Kunze, B.; Winking, H.; Weile, C.; Römer, I.; Hemberger, M.; Fundele, R.; Sharma, T.; et al. Silencing of the Y-chromosomal gene tspy during murine evolution. *Mamm. Genome* **2000**, *11*, 288–291. [[CrossRef](#)] [[PubMed](#)]
97. Manz, E.; Vogel, T.; Glatzel, P.; Schmidtke, J. Identification of an equine Y chromosome specific gene locus (eTSPY) with potential in preimplantation sex diagnosis. *Theriogenology* **1998**, *1*, 364. [[CrossRef](#)]
98. Frank, S.; Thilo, D.; Joachim, A.; Tanja, V.; Martin, W.; Jörg, S. Testis-Specific Protein, Y-Encoded (TSPY) Expression in Testicular Tissues. *Hum. Mol. Genet.* **1996**, *5*, 1801–1807.
99. Schubert, S.; Skawran, B.; Dechend, F.; Nayernia, K.; Meinhardt, A.; Nanda, I.; Schmid, M.; Engel, W.; Schmidtke, J. Generation and characterization of a transgenic mouse with a functional human TSPY. *Biol. Reprod.* **2003**, *69*, 968–975. [[CrossRef](#)] [[PubMed](#)]
100. Kido, T.; Lau, Y.F. A Cre gene directed by a human TSPY promoter is specific for germ cells and neurons. *Genesis* **2005**, *42*, 263–275. [[CrossRef](#)]
101. Hecht, N.B.; Bower, P.A.; Waters, S.H.; Yelick, P.C.; Distel, R.J. Evidence for haploid expression of mouse testicular genes. *Exp. Cell Res.* **1986**, *164*, 183–190. [[CrossRef](#)]
102. Peschon, J.J.; Behringer, R.R.; Palmiter, R.D.; Brinster, R.L. Expression of mouse protamine 1 genes in transgenic mice. *Ann. N. Y. Acad. Sci.* **1989**, *564*, 186–197. [[CrossRef](#)]
103. Peschon, J.J.; Behringer, R.R.; Brinster, R.L.; Palmiter, R.D. Spermatid-specific expression of protamine 1 in transgenic mice. *Proc. Natl. Acad. Sci. USA* **1987**, *84*, 5316–5319. [[CrossRef](#)] [[PubMed](#)]
104. Behringer, R.R.; Peschon, J.J.; Messing, A.; Gartside, C.L.; Hauschka, S.D.; Palmiter, R.D.; Brinster, R.L. Heart and bone tumors in transgenic mice. *Proc. Natl. Acad. Sci. USA* **1988**, *85*, 2648–2652. [[CrossRef](#)]
105. Schmidt, E.E.; Taylor, D.S.; Prigge, J.R.; Barnett, S.; Capecchi, M.R. Illegitimate Cre-dependent chromosome rearrangements in transgenic mouse spermatids. *Proc. Natl. Acad. Sci. USA* **2000**, *97*, 13702–13707. [[CrossRef](#)] [[PubMed](#)]
106. Gobé, C.; Ialy-Radio, C. Generation and Characterization of a Transgenic Mouse That Specifically Expresses the Cre Recombinase in Spermatids. *Genes* **2023**, *14*, 983. [[CrossRef](#)] [[PubMed](#)]
107. Ramachandran, S.; Palanisamy, V. Horizontal transfer of RNAs: Exosomes as mediators of intercellular communication. *Wiley Interdiscip. Rev. RNA* **2012**, *3*, 286–293. [[CrossRef](#)] [[PubMed](#)]
108. Kong, S.; Liang, G.; Tu, Z.; Chen, D.; Wang, H. Generation of Elf5-Cre knockin mouse strain for trophoblast-specific gene manipulation. *Genesis* **2018**, *56*, e23101. [[CrossRef](#)] [[PubMed](#)]
109. Zhou, J.; Ng, A.Y.; Tymms, M.J.; Jermini, L.S.; Seth, A.K.; Thomas, R.S.; Kola, I. A novel transcription factor, ELF5, belongs to the ELF subfamily of ETS genes and maps to human chromosome 11p13–15, a region subject to LOH and rearrangement in human carcinoma cell lines. *Oncogene* **1998**, *17*, 2719–2732. [[CrossRef](#)] [[PubMed](#)]
110. Oettgen, P.; Kas, K.; Dube, A.; Gu, X.; Grall, F.; Thamrongsak, U.; Akbarali, Y.; Finger, E.; Boltax, J.; Endress, G. Characterization of ESE-2, a novel ESE-1-related Ets transcription factor that is restricted to glandular epithelium and differentiated keratinocytes. *J. Biol. Chem.* **1999**, *274*, 29439–29452. [[CrossRef](#)]
111. Sada, A.; Suzuki, A.; Suzuki, H.; Saga, Y. The RNA-binding protein NANOS2 is required to maintain murine spermatogonial stem cells. *Science* **2009**, *325*, 1394–1398. [[CrossRef](#)]
112. Saga, Y. Function of Nanos2 in the male germ cell lineage in mice. *Cell Mol. Life Sci.* **2010**, *67*, 3815–3822. [[CrossRef](#)]
113. Tsuda, M.; Sasaoka, Y.; Kiso, M.; Abe, K.; Haraguchi, S.; Kobayashi, S.; Saga, Y. Conserved role of nanos proteins in germ cell development. *Science* **2003**, *301*, 1239–1241. [[CrossRef](#)] [[PubMed](#)]
114. Brzezinski, J.A.t.; Uoon Park, K.; Reh, T.A. Blimp1 (Prdm1) prevents re-specification of photoreceptors into retinal bipolar cells by restricting competence. *Dev. Biol.* **2013**, *384*, 194–204. [[CrossRef](#)] [[PubMed](#)]
115. Lei, Z.; Lin, J.; Li, X.; Li, S.; Zhou, H.; Araki, Y.; Lan, Z.J. Postnatal male germ-cell expression of cre recombinase in Tex101-iCre transgenic mice. *Genesis* **2010**, *48*, 717–722. [[CrossRef](#)] [[PubMed](#)]
116. Li, S.; Lan, Z.J.; Li, X.; Lin, J.; Lei, Z. Role of postnatal expression of fgfr1 and fgfr2 in testicular germ cells on spermatogenesis and fertility in mice. *J. Reprod. Infertil.* **2014**, *15*, 122–133. [[PubMed](#)]
117. Hara, K.; Nakagawa, T.; Enomoto, H.; Suzuki, M.; Yamamoto, M.; Simons, B.D.; Yoshida, S. Mouse Spermatogenic Stem Cells Continually Interconvert between Equipotent Singly Isolated and Syncytial States. *Cell Stem Cell* **2014**, *14*, 658–672. [[CrossRef](#)] [[PubMed](#)]

118. Davis, T.K.; Hoshi, M.; Jain, S. Stage specific requirement of Gfra1 in the ureteric epithelium during kidney development. *Mech. Dev.* **2013**, *130*, 506–518. [[CrossRef](#)] [[PubMed](#)]
119. Ruzankina, Y.; Pinzon-Guzman, C.; Asare, A.; Ong, T.; Pontano, L.; Cotsarelis, G.; Zediak, V.P.; Velez, M.; Bhandoola, A.; Brown, E. Deletion of the developmentally essential gene ATR in adult mice leads to age-related phenotypes and stem cell loss. *Cell Stem Cell* **2007**, *1*, 113–126. [[CrossRef](#)]
120. Seibler, J.; Zevnik, B.; Küter-Luks, B.; Andreas, S.; Kern, H.; Hennek, T.; Rode, A.; Heimann, C.; Faust, N.; Kauselmann, G. Rapid generation of inducible mouse mutants. *Nucleic Acids Res.* **2003**, *31*, e12. [[CrossRef](#)]
121. Nelson, R.D.; Stricklett, P.; Gustafson, C.; Stevens, A.; Ausiello, D.; Brown, D.; Kohan, D.E. Expression of an AQP2 Cre recombinase transgene in kidney and male reproductive system of transgenic mice. *Am. J. Physiol.* **1998**, *275*, C216–C226. [[CrossRef](#)]
122. Inselman, A.L.; Nakamura, N.; Brown, P.R.; Willis, W.D.; Goulding, E.H.; Eddy, E.M. Heat shock protein 2 promoter drives Cre expression in spermatocytes of transgenic mice. *Genesis* **2010**, *48*, 114–120. [[CrossRef](#)] [[PubMed](#)]
123. Rupik, W.; Stawierej, A.; Stolarczyk, I.; Widłak, W. Promoter of the heat shock testis-specific Hsp70.2/Hst70 gene is active in nervous system during embryonic development of mice. *Anat. Embryol.* **2006**, *211*, 631–638. [[CrossRef](#)] [[PubMed](#)]
124. Ando, H.; Haruna, Y.; Miyazaki, J.; Okabe, M.; Nakanishi, Y. Spermatocyte-specific gene excision by targeted expression of Cre recombinase. *Biochem. Biophys. Res. Commun.* **2000**, *272*, 125–128. [[CrossRef](#)] [[PubMed](#)]
125. Bhullar, B.; Schmidt, J.V.; Truong, T.; Rancourt, D.; van der Hoorn, F.A. Germ cell specific promoter drives ectopic transgene expression during embryogenesis. *Mol. Reprod. Dev. Inc. Gamete Res.* **2001**, *59*, 25–32. [[CrossRef](#)] [[PubMed](#)]
126. Chi, R.A.; Xu, X.; Li, J.L.; Xu, X.; Hu, G.; Brown, P.; Willson, C.; Kirsanov, O.; Geyer, C.; Huang, C.L.; et al. WNK1 is required during male pachynema to sustain fertility. *iScience* **2023**, *26*, 107616. [[CrossRef](#)] [[PubMed](#)]
127. Winuthayanon, W.; Hewitt, S.C.; Orvis, G.D.; Behringer, R.R.; Korach, K.S. Uterine epithelial estrogen receptor α is dispensable for proliferation but essential for complete biological and biochemical responses. *Proc. Natl. Acad. Sci. USA* **2010**, *107*, 19272–19277. [[CrossRef](#)] [[PubMed](#)]
128. Bergqvist, I.; Eriksson, B.; Eriksson, M.; Holmberg, D. Transgenic Cre recombinase expression in germ cells and early embryogenesis directs homogeneous and ubiquitous deletion of loxP-flanked gene segments. *FEBS Lett.* **1998**, *438*, 76–80. [[CrossRef](#)] [[PubMed](#)]
129. Choi, C.I.; Yoon, S.P.; Choi, J.M.; Kim, S.S.; Lee, Y.D.; Birnbaumer, L.; Suh-Kim, H. Simultaneous deletion of floxed genes mediated by CaMKII α -Cre in the brain and in male germ cells: Application to conditional and conventional disruption of Go α . *Exp. Mol. Med.* **2014**, *46*, e93. [[CrossRef](#)] [[PubMed](#)]
130. Tsien, J.Z.; Chen, D.F.; Gerber, D.; Tom, C.; Mercer, E.H.; Anderson, D.J.; Mayford, M.; Kandel, E.R.; Tonegawa, S. Subregion- and cell type-restricted gene knockout in mouse brain. *Cell* **1996**, *87*, 1317–1326. [[CrossRef](#)]
131. Rempe, D.; Vangeison, G.; Hamilton, J.; Li, Y.; Jepson, M.; Federoff, H. Synapsin I Cre transgene expression in male mice produces germline recombination in progeny. *Genesis* **2006**, *44*, 44–49. [[CrossRef](#)]
132. Zhu, Y.; Romero, M.I.; Ghosh, P.; Ye, Z.; Charnay, P.; Rushing, E.J.; Marth, J.D.; Parada, L.F. Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain. *Genes Dev.* **2001**, *15*, 859–876. [[CrossRef](#)] [[PubMed](#)]
133. Larney, C.; Bailey, T.L.; Koopman, P. Switching on sex: Transcriptional regulation of the testis-determining gene. *Development* **2014**, *141*, 2195–2205. [[CrossRef](#)] [[PubMed](#)]
134. Ito, M.; Yokouchi, K.; Yoshida, K.; Kano, K.; Naito, K.; Miyazaki, J.I.; Tojo, H. Investigation of the fate of Sry-expressing cells using an in vivo Cre/loxP system. *Dev. Growth Differ.* **2006**, *48*, 41–47. [[CrossRef](#)]
135. Ito, M.; Yokouchi, K.; Naito, K.; Endo, H.; Hakamata, Y.; Miyazaki, J.I.; Tojo, H. In vitro Cre/loxP system in cells from developing gonads: Investigation of the Sry promoter. *Dev. Growth Differ.* **2002**, *44*, 549–557. [[CrossRef](#)]
136. Sargent, K.M.; McFee, R.M.; Spuri Gomes, R.; Cupp, A.S. Vascular endothelial growth factor A: Just one of multiple mechanisms for sex-specific vascular development within the testis? *J. Endocrinol.* **2015**, *227*, R31–R50. [[CrossRef](#)]
137. Akiyama, H.; Kim, J.-E.; Nakashima, K.; Balmes, G.; Iwai, N.; Deng, J.M.; Zhang, Z.; Martin, J.F.; Behringer, R.R.; Nakamura, T. Osteo-chondroprogenitor cells are derived from Sox9 expressing precursors. *Proc. Natl. Acad. Sci. USA* **2005**, *102*, 14665–14670. [[CrossRef](#)] [[PubMed](#)]
138. Ikeda, Y.; Tagami, A.; Maekawa, M.; Nagai, A. The conditional deletion of steroidogenic factor 1 (Nr5a1) in Sox9-Cre mice compromises testis differentiation. *Sci. Rep.* **2021**, *11*, 4486. [[CrossRef](#)] [[PubMed](#)]
139. Xu, Z.; Wang, W.; Jiang, K.; Yu, Z.; Huang, H.; Wang, F.; Zhou, B.; Chen, T. Embryonic attenuated Wnt/ β -catenin signaling defines niche location and long-term stem cell fate in hair follicle. *eLife* **2015**, *4*, e10567. [[CrossRef](#)]
140. Buaas, F.W.; Gardiner, J.R.; Clayton, S.; Val, P.; Swain, A. In vivo evidence for the crucial role of SF1 in steroid-producing cells of the testis, ovary and adrenal gland. *Development* **2012**, *139*, 4561. [[CrossRef](#)]
141. O'Hara, L.; York, J.P.; Zhang, P.; Smith, L.B. Targeting of GFP-Cre to the mouse Cyp11a1 locus both drives cre recombinase expression in steroidogenic cells and permits generation of Cyp11a1 knock out mice. *PLoS ONE* **2014**, *9*, e84541. [[CrossRef](#)]
142. Darbey, A.; Rebourcet, D.; Curley, M.; Kilcoyne, K.; Jeffery, N.; Reed, N.; Milne, L.; Roesl, C.; Brown, P.; Smith, L.B. A comparison of in vivo viral targeting systems identifies adeno-associated virus serotype 9 (AAV9) as an effective vector for genetic manipulation of Leydig cells in adult mice. *Andrology* **2021**, *9*, 460–473. [[CrossRef](#)] [[PubMed](#)]

143. Gannon, A.L.; Darbey, A.L.; Chensee, G.; Lawrence, B.M. A Novel Model Using AAV9-Cre to Knockout Adult Leydig Cell Gene Expression Reveals a Physiological Role of Glucocorticoid Receptor Signalling in Leydig Cell Function. *Int. J. Mol. Sci.* **2022**, *23*, 5015. [[CrossRef](#)] [[PubMed](#)]
144. Li, K.; Xu, J.; Luo, Y.; Zou, D.; Han, R.; Zhong, S.; Zhao, Q.; Mang, X.; Li, M.; Si, Y.; et al. Panoramic transcriptome analysis and functional screening of long noncoding RNAs in mouse spermatogenesis. *Genome Res.* **2021**, *31*, 13–26. [[CrossRef](#)]
145. Mullen, R.D.; Behringer, R.R. Molecular genetics of Müllerian duct formation, regression and differentiation. *Sex. Dev.* **2014**, *8*, 281–296. [[CrossRef](#)] [[PubMed](#)]
146. Jamin, S.P.; Arango, N.A.; Mishina, Y.; Hanks, M.C.; Behringer, R.R. Requirement of *Bmpr1a* for Müllerian duct regression during male sexual development. *Nat. Genet.* **2002**, *32*, 408–410. [[CrossRef](#)] [[PubMed](#)]
147. Sargent, K.M.; Lu, N.; Clopton, D.T.; Pohlmeier, W.E.; Brauer, V.M.; Ferrara, N.; Silversides, D.W.; Cupp, A.S. Loss of vascular endothelial growth factor A (VEGFA) isoforms in granulosa cells using pDmrt-1-Cre or Amhr2-Cre reduces fertility by arresting follicular development and by reducing litter size in female mice. *PLoS ONE* **2015**, *10*, e0116332. [[CrossRef](#)] [[PubMed](#)]
148. Xu, Q.; Lin, H.-Y.; Yeh, S.-D.; Yu, I.-C.; Wang, R.-S.; Chen, Y.-T.; Zhang, C.; Altuwaijri, S.; Chen, L.-M.; Chuang, K.-H. Infertility with defective spermatogenesis and steroidogenesis in male mice lacking androgen receptor in Leydig cells. *Endocrine* **2007**, *32*, 96–106. [[CrossRef](#)]
149. Fang, X.; Ni, N.; Gao, Y.; Vincent, D.F.; Bartholin, L.; Li, Q.L. A novel mouse model of testicular granulosa cell tumors. *Mol. Hum. Reprod.* **2018**, *24*, 343–356. [[CrossRef](#)]
150. Chauvin, M.; Meisohn, M.-C.; Dasari, S.; May, P.; Iyer, S.; Nguyen, N.; Oliva, E.; Lucchini, Z.; Nagykerly, N.; Kashiwagi, A. Cancer-associated mesothelial cells are regulated by the anti-Müllerian hormone axis. *Cell Rep.* **2023**, *42*, 112730. [[CrossRef](#)]
151. Shami, A.N.; Zheng, X.; Munyoki, S.K.; Ma, Q.; Manske, G.L.; Green, C.D.; Sukhwani, M.; Orwig, K.E.; Li, J.Z.; Hammoud, S.S. Single-Cell RNA Sequencing of Human, Macaque, and Mouse Testes Uncovers Conserved and Divergent Features of Mammalian Spermatogenesis. *Dev. Cell* **2020**, *54*, 529–547.e12. [[CrossRef](#)]
152. Ma, Y.; Ma, Q.W.; Sun, Y. The emerging role of extracellular vesicles in the testis. *Hum. Reprod.* **2023**, *38*, 334–351. [[CrossRef](#)]
153. Abe, S.I. Behavior and Functional Roles of CD34⁺ Mesenchymal Cells in Mammalian Testes. *Int. J. Mol. Sci.* **2022**, *23*, 9585. [[CrossRef](#)] [[PubMed](#)]
154. Chen, L.Y.; Brown, P.R.; Willis, W.B.; Eddy, E.M. Peritubular myoid cells participate in male mouse spermatogonial stem cell maintenance. *Endocrinology* **2014**, *155*, 4964–4974. [[CrossRef](#)] [[PubMed](#)]
155. Xin, H.B.; Deng, K.Y.; Rishniw, M.; Ji, G.; Kotlikoff, M.I. Smooth muscle expression of Cre recombinase and eGFP in transgenic mice. *Physiol. Genom.* **2002**, *10*, 211–215. [[CrossRef](#)] [[PubMed](#)]
156. Chen, L.Y.; Willis, W.D.; Eddy, E.M. Targeting the *Gdnf* Gene in peritubular myoid cells disrupts undifferentiated spermatogonial cell development. *Proc. Natl. Acad. Sci. USA* **2016**, *113*, 1829–1834. [[CrossRef](#)] [[PubMed](#)]
157. Huang, Q.; Man, Y. Inactivation of *Cops5* in Smooth Muscle Cells Causes Abnormal Reproductive Hormone Homeostasis and Development in Mice. *Endocrinology* **2023**, *164*, bqad062. [[CrossRef](#)] [[PubMed](#)]
158. Bulut, G.B.; Alencar, G.F.; Owsiany, K.M.; Nguyen, A.T.; Karnewar, S.; Haskins, R.M.; Waller, L.K.; Cherepanova, O.A.; Deaton, R.A.; Shankman, L.S.; et al. KLF4 (Kruppel-Like Factor 4)-Dependent Perivascular Plasticity Contributes to Adipose Tissue inflammation. *Arterioscler. Thromb. Vasc. Biol.* **2021**, *41*, 284–301. [[CrossRef](#)]
159. Eddy, E.M.; Chen, L.Y. Reply to Chen and Liu: Role of GDNF from peritubular myoid cells in the testis stem cell niche. *Proc. Natl. Acad. Sci. USA* **2016**, *113*, E2353. [[CrossRef](#)] [[PubMed](#)]
160. DeFalco, T.; Potter, S.J.; Williams, A.V.; Waller, B.; Kan, M.J.; Capel, B. Macrophages contribute to the spermatogonial niche in the adult testis. *Cell Rep.* **2015**, *12*, 1107–1119. [[CrossRef](#)] [[PubMed](#)]
161. Jung, S.; Aliberti, J.; Graemmel, P.; Sunshine, M.J.; Kreutzberg, G.W.; Sher, A.; Littman, D.R. Analysis of Fractalkine Receptor CX3CR1 Function by Targeted Deletion and Green Fluorescent Protein Reporter Gene Insertion. *Mol. Cell. Biol.* **2000**, *20*, 4106–4114. [[CrossRef](#)] [[PubMed](#)]
162. Kisanuki, Y.Y.; Hammer, R.E.; Miyazaki, J.-i.; Williams, S.C.; Richardson, J.A.; Yanagisawa, M. Tie2-Cre transgenic mice: A new model for endothelial cell-lineage analysis in vivo. *Dev. Biol.* **2001**, *230*, 230–242. [[CrossRef](#)]
163. O'Hara, L.; Smith, L.B. Androgen receptor signalling in Vascular Endothelial cells is dispensable for spermatogenesis and male fertility. *BMC Res. Notes* **2012**, *5*, 16. [[CrossRef](#)]
164. Meng, R.; Cai, W.K.; Xu, W.M.; Feng, Q.; Wang, P.; Huang, Y.H.; Fan, Y.X.; Zhou, T.; Yang, Q.; Li, Z.R.; et al. Generation and identification of endothelial-specific *Hrh2* knockout mice. *Transgenic Res.* **2021**, *30*, 251–261. [[CrossRef](#)] [[PubMed](#)]
165. Kilani, B.; Gourdou-Latyszenok, V.; Guy, A.; Bats, M.L.; Peghaire, C.; Parrens, M.; Renault, M.A.; Duplâa, C.; Villeval, J.L.; Rautou, P.E.; et al. Comparison of endothelial promoter efficiency and specificity in mice reveals a subset of *Pdgfb*-positive hematopoietic cells. *J. Thromb. Haemost. JTH* **2019**, *17*, 827–840. [[CrossRef](#)]
166. Rumianek, A.N.; Davies, B.; Channon, K.M.; Greaves, D.R.; Purvis, G.S.D. A Human CD68 Promoter-Driven Inducible Cre-Recombinase Mouse Line Allows Specific Targeting of Tissue Resident Macrophages. *Front. Immunol.* **2022**, *13*, 918636. [[CrossRef](#)] [[PubMed](#)]
167. Rumianek, A.N. *New Methods to Study Macrophage Biology In Vitro and In Vivo*; University of Oxford: Oxford, UK, 2022.
168. Hashimoto, M.; Kimura, S.; Kanno, C.; Yanagawa, Y.; Watanabe, T.; Okabe, J.; Takahashi, E.; Nagano, M.; Kitamura, H. Macrophage ubiquitin-specific protease 2 contributes to motility, hyperactivation, capacitation, and in vitro fertilization activity of mouse sperm. *Cell Mol. Life Sci.* **2021**, *78*, 2929–2948. [[CrossRef](#)]

169. James, E.R.; Carrell, D.T.; Aston, K.I.; Jenkins, T.G.; Yeste, M.; Salas-Huetos, A. The Role of the Epididymis and the Contribution of Epididymosomes to Mammalian Reproduction. *Int. J. Mol. Sci.* **2020**, *21*, 5377. [[CrossRef](#)] [[PubMed](#)]
170. Cornwall, G.A. New insights into epididymal biology and function. *Human Reprod. Update* **2009**, *15*, 213–227. [[CrossRef](#)]
171. Jalkanen, J.; Huhtaniemi, I.; Poutanen, M. Discovery and characterization of new epididymis-specific beta-defensins in mice. *Biochim. Biophys. Acta BBA—Gene Struct. Expr.* **2005**, *1730*, 22–30. [[CrossRef](#)]
172. Björkgren, I.; Alvarez, L.; Blank, N.; Balbach, M.; Turunen, H.; Laajala, T.D.; Toivanen, J.; Krutskikh, A.; Wahlberg, N.; Huhtaniemi, I.; et al. Targeted inactivation of the mouse epididymal beta-defensin 41 alters sperm flagellar beat pattern and zona pellucida binding. *Mol. Cell. Endocrinol.* **2016**, *427*, 143–154. [[CrossRef](#)]
173. Björkgren, I.; Saastamoinen, L.; Krutskikh, A.; Huhtaniemi, I.; Poutanen, M.; Sipilä, P. Dicer1 ablation in the mouse epididymis causes dedifferentiation of the epithelium and imbalance in sex steroid signaling. *PLoS ONE* **2012**, *7*, e38457. [[CrossRef](#)]
174. Björkgren, I.; Gylling, H.; Turunen, H.; Huhtaniemi, I.; Strauss, L.; Poutanen, M.; Sipilä, P. Imbalanced lipid homeostasis in the conditional Dicer1 knockout mouse epididymis causes instability of the sperm membrane. *FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol.* **2015**, *29*, 433–442. [[CrossRef](#)] [[PubMed](#)]
175. Penttinen, J.; Pujianto, D.A.; Sipilä, P.; Huhtaniemi, I.; Poutanen, M. Discovery in silico and characterization in vitro of novel genes exclusively expressed in the mouse epididymis. *Mol. Endocrinol.* **2003**, *17*, 2138–2151. [[CrossRef](#)] [[PubMed](#)]
176. Krutskikh, A.; Poliandri, A.; Cabrera-Sharp, V.; Dacheux, J.L.; Poutanen, M.; Huhtaniemi, I. Epididymal protein Rnase10 is required for post-testicular sperm maturation and male fertility. *FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol.* **2012**, *26*, 4198–4209. [[CrossRef](#)] [[PubMed](#)]
177. Krutskikh, A.; De Gendt, K.; Sharp, V.; Verhoeven, G.; Poutanen, M.; Huhtaniemi, I. Targeted Inactivation of the Androgen Receptor Gene in Murine Proximal Epididymis Causes Epithelial Hypotrophy and Obstructive Azoospermia. *Endocrinology* **2011**, *152*, 689–696. [[CrossRef](#)] [[PubMed](#)]
178. Reddy, T.; Gibbs, G.M.; Merriner, D.J.; Kerr, J.B.; O'Bryan, M.K. Cysteine-rich secretory proteins are not exclusively expressed in the male reproductive tract. *Dev. Dyn. Off. Publ. Am. Assoc. Anat.* **2008**, *237*, 3313–3323. [[CrossRef](#)] [[PubMed](#)]
179. Nolan, M.A.; Wu, L.; Bang, H.J.; Jelinsky, S.A.; Roberts, K.P.; Turner, T.T.; Kopf, G.S.; Johnston, D.S. Identification of rat cysteine-rich secretory protein 4 (Crisp4) as the ortholog to human CRISP1 and mouse Crisp4. *Biol. Reprod.* **2006**, *74*, 984–991. [[CrossRef](#)] [[PubMed](#)]
180. Turunen, H.T.; Sipilä, P.; Krutskikh, A.; Toivanen, J.; Mankonen, H.; Hämäläinen, V.; Björkgren, I.; Huhtaniemi, I.; Poutanen, M. Loss of cysteine-rich secretory protein 4 (Crisp4) leads to deficiency in sperm-zona pellucida interaction in mice. *Biol. Reprod.* **2012**, *86*, 11–18. [[CrossRef](#)] [[PubMed](#)]
181. Munoz, M.W.; Carvajal, G.; Curci, L.; Gonzalez, S.N.; Cuasnicu, P.S. Relevance of CRISP proteins for epididymal physiology, fertilization, and fertility. *Andrology* **2019**, *7*, 610–617. [[CrossRef](#)] [[PubMed](#)]
182. Carvajal, G.; Brukman, N.G.; Muñoz, M.W.; Battistone, M.A.; Guazzone, V.A.; Ikawa, M.; Haruhiko, M.; Lustig, L.; Breton, S.; Cuasnicu, P.S. Impaired male fertility and abnormal epididymal epithelium differentiation in mice lacking CRISP1 and CRISP4. *Sci. Rep.* **2018**, *8*, 17531. [[CrossRef](#)]
183. Suzuki, K.; Lareyre, J.J.; Sánchez, D.; Gutierrez, G.; Araki, Y.; Matusik, R.J.; Orgebin-Crist, M.C. Molecular evolution of epididymal lipocalin genes localized on mouse chromosome 2. *Gene* **2004**, *339*, 49–59. [[CrossRef](#)]
184. Lareyre, J.J.; Reid, K.; Nelson, C.; Kasper, S.; Rennie, P.S.; Orgebin-Crist, M.C.; Matusik, R.J. Characterization of an androgen-specific response region within the 5' flanking region of the murine epididymal retinoic acid binding protein gene. *Biol. Reprod.* **2000**, *63*, 1881–1892. [[CrossRef](#)] [[PubMed](#)]
185. Suzuki, K.; Yu, X.; Chaurand, P.; Araki, Y.; Lareyre, J.J.; Caprioli, R.M.; Orgebin-Crist, M.C.; Matusik, R.J. Epididymis-specific lipocalin promoters. *Asian J. Androl.* **2007**, *9*, 515–521. [[CrossRef](#)] [[PubMed](#)]
186. Wen, Z.; Liu, D.; Zhu, H.; Sun, X.; Xiao, Y.; Lin, Z.; Zhang, A.; Ye, C.; Gao, J. Deficiency for Lcn8 causes epididymal sperm maturation defects in mice. *Biochem. Biophys. Res. Commun.* **2021**, *548*, 7–13. [[CrossRef](#)] [[PubMed](#)]
187. Sakurai, N.; Fujihara, Y. CRISPR/Cas9-mediated disruption of *lipocalins*, *Ly6g5b*, and *Ly6g5c* causes male subfertility in mice. *Andrology* **2022**, 1–10. [[CrossRef](#)] [[PubMed](#)]
188. Xie, S.; Xu, J.; Ma, W.; Liu, Q.; Han, J.; Yao, G.; Huang, X.; Zhang, Y. Lcn5 promoter directs the region-specific expression of cre recombinase in caput epididymidis of transgenic mice. *Biol. Reprod.* **2013**, *88*, 71. [[CrossRef](#)] [[PubMed](#)]
189. Xu, J.; Yao, G.; Ru, Y.; Xie, S. Expression of tamoxifen-inducible CRE recombinase in Lcn5-CreER(T2) transgenic mouse caput epididymis. *Mol. Reprod. Dev.* **2017**, *84*, 257–264. [[CrossRef](#)] [[PubMed](#)]
190. Gong, Q.Q.; Dou, Z.L.; Wang, X.; Zhang, K.Y.; Chen, H.; Gao, J.G.; Sun, X.Y. Epididymal initial segment-specific Cre recombinase activity in Lcn8-Cre knock-in mice. *Mol. Biol. Rep.* **2021**, *48*, 6015–6023. [[CrossRef](#)] [[PubMed](#)]
191. Gong, Q.Q.; Wang, X.; Dou, Z.L.; Zhang, K.Y.; Liu, X.G.; Gao, J.G.; Sun, X.Y. A novel mouse line with epididymal initial segment-specific expression of Cre recombinase driven by the endogenous promoter. *PLoS ONE* **2021**, *16*, e0254802. [[CrossRef](#)] [[PubMed](#)]
192. Dai, P.; Qiao, F.; Chen, Y.; Chan, D.Y.L.; Yim, H.C.H.; Fok, K.L.; Chen, H. SARS-CoV-2 and male infertility: From short- to long-term impacts. *J. Endocrinol. Invest.* **2023**, *46*, 1491–1507. [[CrossRef](#)]
193. Wu, X.; Wu, J.; Huang, J.; Powell, W.C.; Zhang, J.; Matusik, R.J.; Sangiorgi, F.O.; Maxson, R.E.; Sucov, H.M.; Roy-Burman, P. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. *Mech. Dev.* **2001**, *101*, 61–69. [[CrossRef](#)]

194. Jin, C.; McKeehan, K.; Wang, F. Transgenic mouse with high Cre recombinase activity in all prostate lobes, seminal vesicle, and ductus deferens. *Prostate* **2003**, *57*, 160–164. [[CrossRef](#)] [[PubMed](#)]
195. Wang, H.; Yang, H.; Shivalila, C.S.; Dawlaty, M.M.; Cheng, A.W.; Zhang, F.; Jaenisch, R. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. *Cell* **2013**, *153*, 910–918. [[CrossRef](#)] [[PubMed](#)]
196. Archambeault, D.R.; Matzuk, M.M. Disrupting the male germ line to find infertility and contraception targets. In *Annales D'endocrinologie*; Elsevier Masson: Amsterdam, The Netherlands, 2014; pp. 101–108.
197. Soriano, P. Generalized lacZ expression with the ROSA26 Cre reporter strain. *Nat. Genet.* **1999**, *21*, 70–71. [[CrossRef](#)] [[PubMed](#)]
198. He, L.; Li, Y.; Li, Y.; Pu, W.; Huang, X.; Tian, X.; Wang, Y.; Zhang, H.; Liu, Q.; Zhang, L. Enhancing the precision of genetic lineage tracing using dual recombinases. *Nat. Med.* **2017**, *23*, 1488–1498. [[CrossRef](#)]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.